

# CITATION REPORT

List of articles citing

An integrated genomic analysis of human glioblastoma multi

DOI: 10.1126/science.1164382  
Science, 2008, 321, 1807-12.

**Source:** <https://exaly.com/paper-pdf/43581600/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2286	.		
2285	Clinical application of the blink reflex with stimulation of the mental nerve in lesions of the inferior alveolar nerve. <b>1994</b> , 44, 2356-61		25
2284	Theoretical Analysis of Gas Breakdown Characteristic through a Narrow Discharge Tube. <b>1995</b> , 34, 3671-3674		5
2283	Tumors of the central nervous system. <b>2000</b> , 460-482		
2282	Essential roles of the bHLH transcription factor Hrt2 in repression of atrial gene expression and maintenance of postnatal cardiac function. <b>2007</b> , 104, 7975-80		92
2281	Analysis of the IDH1 codon 132 mutation in brain tumors. <b>2008</b> , 116, 597-602		786
2280	News in brief. <b>2008</b> , 5, 919-919		
2279	Pathways to cancer therapy. <b>2008</b> , 7, 875-6		29
2278	Determinants of VO2 max decline with aging: an integrated perspective. <b>2008</b> , 33, 130-40		89
2277	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. <i>Science</i> , <b>2008</b> , 321, 1801-6	33.3	3223
2276	Defining a candidate lung cancer gene. <b>2008</b> , 100, 1564-5		3
2275	Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. <b>2008</b> , 10, 767-77		162
2274	Systems biology and cancer prevention: all options on the table. <b>2008</b> , 2, 307-19		9
2273	Theoretical and Experimental Approaches to Address Possible Thresholds of Response in Carcinogenicity. <b>2008</b> , 30, 150-159		3
2272	Divide and conquer: progress in the molecular stratification of cancer. <b>2009</b> , 50, 464-73		4
2271	Educational and social-ethical issues in the pursuit of molecular medicine. <b>2009</b> , 15, 60-3		5
2270	[Médicine/Sciences as time goes by]. <b>2009</b> , 25, 3-4		0

2269	Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. <b>2009</b> , 4, e5209	88
2268	Glioblastoma formation from cell population depleted of Prominin1-expressing cells. <b>2009</b> , 4, e6869	47
2267	Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. <b>2009</b> , 4, e7033	133
2266	Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs. <b>2009</b> , 4, e7157	24
2265	Sequence and structure signatures of cancer mutation hotspots in protein kinases. <b>2009</b> , 4, e7485	57
2264	Meta-analysis of cancer microarray data reveals signaling pathway hotspots. <b>2009</b> ,	
2263	Using Gene Pair Combinations to Improve the Accuracy of the PAM Classifier. <b>2009</b> ,	1
2262	Emergence of single-molecule sequencing and potential for molecular diagnostic applications. <b>2009</b> , 9, 659-66	25
2261	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. <b>2009</b> , 106, 16996-7001	218
2260	High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. <b>2009</b> , 34, 489-506	31
2259	IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. <b>2009</b> , 73, 1792-5	168
2258	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. <b>2009</b> , 15, 6002-7	524
2257	Multiplex padlock targeted sequencing reveals human hypermutable CpG variations. <b>2009</b> , 19, 1606-15	59
2256	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. <b>2009</b> , 15, 4622-9	291
2255	Advances in the genetics of glioblastoma: are we reaching critical mass?. <b>2009</b> , 5, 419-26	99
2254	Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. <b>2009</b> , 2, 1050-8	42
2253	A novel algorithm for detecting differentially regulated paths based on gene set enrichment analysis. <b>2009</b> , 25, 2787-94	46
2252	Identification of survival genes in human glioblastoma cells by small interfering RNA screening. <b>2009</b> , 76, 1246-55	54

2251	Challenges in the search for drugs to treat central nervous system disorders. <b>2009</b> , 329, 404-11	84
2250	Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. <b>2009</b> , 69, 5901-7	42
2249	Cancer genome sequencing--an interim analysis. <b>2009</b> , 69, 4948-50	60
2248	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. <b>2009</b> , 106, 12944-9	143
2247	Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. <b>2009</b> , 106, 20258-63	64
2246	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. <i>Science</i> , <b>2009</b> , 324, 217-221	33.3 608
2245	Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. <b>2009</b> , 8, 1806-7	33
2244	Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. <b>2009</b> , 101, 973-82	87
2243	Gazing deeper into cancer. <b>2009</b> , 2, 3-3	
2242	Molecular classification of solid tumours: towards pathway-driven therapeutics. <b>2009</b> , 100, 1517-22	59
2241	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. <b>2009</b> , 69, 6889-98	120
2240	Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. <b>2009</b> , 15, 7124-9	28
2239	Protective roles of matrix metalloproteinases: from mouse models to human cancer. <b>2009</b> , 8, 3657-62	103
2238	Copy number variation has little impact on bead-array-based measures of DNA methylation. <b>2009</b> , 25, 1999-2005	32
2237	MODBASE, a database of annotated comparative protein structure models and associated resources. <b>2009</b> , 37, D347-54	143
2236	The role of autophagy in sensitizing malignant glioma cells to radiation therapy. <b>2009</b> , 41, 341-51	100
2235	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. <b>2009</b> , 106, 18351-6	226
2234	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. <b>2009</b> , 69, 4252-9	201

2233	Cancer. Puzzling patterns of predisposition. <i>Science</i> , <b>2009</b> , 324, 192-4	33-3	49
2232	Paxillin-kinase-linker tyrosine phosphorylation regulates directional cell migration. <b>2009</b> , 20, 4706-19		48
2231	Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. <b>2009</b> , 69, 2026-33		37
2230	A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. <b>2009</b> , 69, 8150-6		140
2229	Mutant metabolic enzymes are at the origin of gliomas. <b>2009</b> , 69, 9157-9		117
2228	RIGging functional outcomes in glioma cells: new insights into LRIG proteins in malignant gliomas. <b>2009</b> , 8, 1024-6		2
2227	Systematically linking drug susceptibility to cancer genome aberrations. <b>2009</b> , 8, 3652-6		3
2226	Enhancing radiosensitivity: targeting the DNA repair pathways. <b>2009</b> , 8, 665-70		47
2225	A network model of a cooperative genetic landscape in brain tumors. <b>2009</b> , 302, 261-75		144
2224	Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. <b>2009</b> , 108, 273-89		31
2223	Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas. <b>2009</b> , 5, 303-4		5
2222	IDH1 and IDH2 mutations in gliomas. <b>2009</b> , 360, 2248; author reply 2249		89
2221	Cancer genomes--continuing progress. <b>2009</b> , 361, 1111-2		5
2220	Hypoxia-induced mediators and neurologic disease. <b>2009</b> , 73, 560-5		16
2219	Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. <b>2009</b> , 284, 22436-22443		21
2218	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. <b>2009</b> , 23, 1327-37		403
2217	Genetic mutations associated with cigarette smoking in pancreatic cancer. <b>2009</b> , 69, 3681-8		88
2216	Saturation density of skin fibroblasts as a quantitative screen for human cancer susceptibility. <b>2009</b> , 18, 2366-72		4

2215	A drosophila model for EGFR-Ras and PI3K-dependent human glioma. <b>2009</b> , 5, e1000374	145
2214	Oncogenic EGFR signaling networks in glioma. <b>2009</b> , 2, re6	239
2213	p53 Pathway Alterations in Brain Tumors. <b>2009</b> , 283-314	2
2212	Exploiting synthetic lethal interactions for targeted cancer therapy. <b>2009</b> , 8, 3112-9	87
2211	Emerging roles of the EBF family of transcription factors in tumor suppression. <b>2009</b> , 7, 1893-901	63
2210	Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. <b>2009</b> , 11, 803-18	32
2209	Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. <b>2009</b> , 11, 477-87	99
2208	Mutation patterns in cancer genomes. <b>2009</b> , 106, 21766-70	62
2207	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. <b>2009</b> , 69, 9065-72	437
2206	BINARY STARS WITH COMPONENTS OF SOLAR TYPE: 25 ORBITS AND SYSTEM MASSES. <b>2009</b> , 138, 1159-1170	15
2205	Molecular neuropathology of gliomas. <b>2009</b> , 10, 184-212	33
2204	Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. <b>2009</b> , 4, e7752	390
2203	EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. <b>2009</b> , 15, 5753-61	70
2202	Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. <b>2009</b> , 69, 7953-9	82
2201	IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. <b>2009</b> , 11, 341-7	435
2200	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. <b>2009</b> , 27, 5650-9	103
2199	Identification of rare cancer driver mutations by network reconstruction. <b>2009</b> , 19, 1570-8	80
2198	Sample type bias in the analysis of cancer genomes. <b>2009</b> , 69, 5630-3	25

2197	ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. <b>2009</b> , 25, 2882-9	34
2196	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. <b>2009</b> , 106, 3964-9	234
2195	Epigenetic mechanisms in glioblastoma multiforme. <b>2009</b> , 19, 188-97	141
2194	Beyond grade: molecular pathology of malignant gliomas. <b>2009</b> , 19, 142-9	28
2193	Neurofibroma development in NF1--insights into tumour initiation. <b>2009</b> , 19, 395-403	27
2192	Deciphering the genetic landscape of cancer--from genes to pathways. <b>2009</b> , 25, 455-62	30
2191	Models for prevention and treatment of cancer: problems vs promises. <b>2009</b> , 78, 1083-94	117
2190	Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. <b>2009</b> , 15, 514-26	199
2189	EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. <b>2009</b> , 16, 9-20	340
2188	Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. <b>2009</b> , 16, 44-54	113
2187	Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. <b>2009</b> , 16, 463-74	241
2186	PI3K regulatory subunits lose control in cancer. <b>2009</b> , 16, 449-50	25
2185	Should individual PI3 kinase isoforms be targeted in cancer?. <b>2009</b> , 21, 199-208	99
2184	Translating biology into clinic: the case of glioblastoma. <b>2009</b> , 21, 311-6	18
2183	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. <b>2009</b> , 30, 7-11	320
2182	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. <b>2009</b> , 125, 353-5	258
2181	Absence of IDH2 codon 172 mutation in common human cancers. <b>2009</b> , 125, 2485-6	17
2180	Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. <b>2009</b> , 220, 538-47	129

2179	Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin. <b>2009</b> , 221, 514-20	28
2178	Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. <b>2009</b> , 1, 338-51	371
2177	Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. <b>2009</b> , 48, 908-24	36
2176	Mutational spectra of human cancer. <b>2009</b> , 125, 493-506	143
2175	Analytical methods for inferring functional effects of single base pair substitutions in human cancers. <b>2009</b> , 126, 481-98	17
2174	Glioblastomes: aspects moléculaires et prise en charge actuelle. <b>2009</b> , 11, 67-71	1
2173	Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. <b>2009</b> , 117, 653-6	66
2172	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. <b>2009</b> , 118, 401-5	223
2171	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <b>2009</b> , 118, 469-74	874
2170	Monoclonal antibody specific for IDH1 R132H mutation. <b>2009</b> , 118, 599-601	330
2169	GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. <b>2009</b> , 118, 603-4	20
2168	Molecular epigenetics and genetics in neuro-oncology. <b>2009</b> , 6, 436-46	43
2167	Targeted therapy for malignant glioma patients: lessons learned and the road ahead. <b>2009</b> , 6, 500-12	71
2166	The evolution and application of techniques in molecular biology to human brain tumors: a 25 year perspective. <b>2009</b> , 92, 261-73	7
2165	Emerging functions of microRNAs in glioblastoma. <b>2009</b> , 92, 297-306	93
2164	Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. <b>2009</b> , 94, 297	7
2163	Origins and clinical implications of the brain tumor stem cell hypothesis. <b>2009</b> , 93, 49-60	29
2162	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. <b>2009</b> , 64, 863-6	7



2161	Tumor biology and cancer therapy - an evolving relationship. <b>2009</b> , 7, 19	10
2160	Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. <b>2009</b> , 4, 43	134
2159	Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. <b>2009</b> , 100, 1996-8	122
2158	Genetic alterations and signaling pathways in the evolution of gliomas. <b>2009</b> , 100, 2235-41	322
2157	From cancer genomes to cancer models: bridging the gaps. <b>2009</b> , 10, 359-66	29
2156	The cancer genome. <b>2009</b> , 458, 719-24	2272
2155	Molecular networks as sensors and drivers of common human diseases. <b>2009</b> , 461, 218-23	589
2154	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <b>2009</b> , 462, 739-44	2558
2153	Genome-wide association study identifies five susceptibility loci for glioma. <b>2009</b> , 41, 899-904	640
2152	Perspectives on the development of imatinib and the future of cancer research. <b>2009</b> , 15, 1149-52	87
2151	High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. <b>2009</b> , 9, 389-99	102
2150	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. <b>2009</b> , 8, 806-23	667
2149	A network view of disease and compound screening. <b>2009</b> , 8, 286-95	219
2148	Targeting the phosphoinositide 3-kinase pathway in cancer. <b>2009</b> , 8, 627-44	1895
2147	Prostate cancer genomics: towards a new understanding. <b>2009</b> , 10, 77-82	98
2146	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. <b>2009</b> , 28, 2773-83	185
2145	Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. <b>2009</b> , 28, 3121-31	74
2144	The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. <b>2009</b> , 28, 3586-96	65

2143	Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence. <b>2009</b> , 28, 1537-48	25
2142	Driving in the melanoma landscape. <b>2009</b> , 18, 506-8	8
2141	PI3K signaling in glioma--animal models and therapeutic challenges. <b>2009</b> , 19, 112-20	93
2140	Genetically engineered mouse models of brain cancer and the promise of preclinical testing. <b>2009</b> , 19, 132-43	118
2139	Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk. <b>2009</b> , 19, 121-31	30
2138	Molecular epidemiology of primary brain tumors. <b>2009</b> , 6, 427-35	72
2137	Understanding the Warburg effect: the metabolic requirements of cell proliferation. <i>Science</i> , <b>2009</b> , 324, 1029-33	33-3 9509
2136	Genetic signature of adult gliomas and correlation with MRI features. <b>2009</b> , 9, 709-20	11
2135	Protein residues that control the reaction trajectory in S-adenosylmethionine radical enzymes: mutagenesis of asparagine 153 and aspartate 155 in Escherichia coli biotin synthase. <b>2009</b> , 48, 2448-58	20
2134	Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. <b>2009</b> , 8, 3044-54	51
2133	Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. <b>2009</b> , 106, 19096-101	971
2132	Identifying Candidate Cancer Genes Based on Their Somatic Mutations Co-Occurring with Cancer Genes in Cancer Genome Profiling. <b>2009</b> ,	
2131	Molecular pathology of oligodendroglial tumors. <b>2009</b> , 171, 25-49	14
2130	In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine. <b>2009</b> , 9, 669-76	18
2129	Stat3 activation is required for the growth of U87 cell-derived tumours in mice. <b>2009</b> , 45, 677-84	35
2128	Principles of cancer therapy: oncogene and non-oncogene addiction. <b>2009</b> , 136, 823-37	1328
2127	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. <b>2009</b> , 137, 821-34	454
2126	Finding and drugging the vulnerabilities of RAS-dependent cancers. <b>2009</b> , 137, 796-8	15

2125	Integrative genomic approaches to understanding cancer. <b>2009</b> , 1790, 478-84	6
2124	A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. <b>2009</b> , 390, 547-51	90
2123	A little CIN may cost a lot: revisiting aneuploidy and cancer. <b>2009</b> , 19, 74-81	52
2122	The molecular determinants of de novo nucleotide biosynthesis in cancer cells. <b>2009</b> , 19, 32-7	224
2121	The side story of stem-like glioma cells. <b>2009</b> , 4, 191-2	8
2120	Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. <b>2009</b> , 4, 568-80	719
2119	Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. <b>2009</b> , 20, 869-76	349
2118	Finding disease-specific coordinated functions by multi-function genes: insight into the coordination mechanisms in diseases. <b>2009</b> , 94, 94-100	15
2117	New drugs for brain tumors? Insights from chemical probing of neural stem cells. <b>2009</b> , 72, 683-7	24
2116	A genomic strategy to elucidate modules of oncogenic pathway signaling networks. <b>2009</b> , 34, 104-14	91
2115	Metabolic enzymes as oncogenes or tumor suppressors. <b>2009</b> , 360, 813-5	179
2114	Molecular origins of cancer: Molecular basis of colorectal cancer. <b>2009</b> , 361, 2449-60	1331
2113	Targeting the DNA damage response in cancer. <b>2009</b> , 109, 2929-50	114
2112	Tumor suppressors and cell metabolism: a recipe for cancer growth. <b>2009</b> , 23, 537-48	742
2111	Tumor-targeted quantum dots can help surgeons find tumor boundaries. <b>2009</b> , 8, 65-71	27
2110	IDH1 and IDH2 mutations in gliomas. <b>2009</b> , 360, 765-73	4220
2109	Glioblastoma multiforme: a review of where we have been and where we are going. <b>2009</b> , 18, 1061-83	358
2108	Is anticancer drug development heading in the right direction?. <b>2009</b> , 69, 1259-62	129

2107	Mutation of FOXL2 in granulosa-cell tumors of the ovary. <b>2009</b> , 360, 2719-29		551
2106	Glioblastoma multiforme: a review of therapeutic targets. <b>2009</b> , 13, 701-18		119
2105	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. <b>2009</b> , 27, 5874-80		625
2104	Peptides as Drugs: Discovery and Development. 1-8		7
2103	Textbook of Personalized Medicine. <b>2009</b> ,		55
2102	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. <b>2009</b> , 11, 448-58, 2 p following 458		92
2101	Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. <i>Science</i> , <b>2009</b> , 324, 261-5	33.3	884
2100	Mitochondria and reactive oxygen species. <b>2009</b> , 53, 885-92		158
2099	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. <i>Science</i> , <b>2009</b> , 325, 1555-9	33.3	680
2098	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. <b>2009</b> , 9, 1815-36		31
2097	Insights into gliomagenesis: systems biology unravels key pathways. <b>2009</b> , 1, 101		1
2096	Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. <b>2009</b> , 23, 351-63		40
2095	Applications of new sequencing technologies for transcriptome analysis. <b>2009</b> , 10, 135-51		392
2094	Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. <b>2009</b> , 18, 1962-75		100
2093	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. <b>2009</b> , 174, 1149-53		757
2092	Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. <b>2009</b> , 10, 508-15		259
2091	Translating biological insights into clinical endpoints in neuro-oncology. <b>2009</b> , 10, 928-9		5
2090	Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. <b>2009</b> , 69, 6660-7		344

2089	Molecular pathways in tumor progression: from discovery to functional understanding. <b>2009</b> , 5, 902-8	26
2088	Applications of genomics in melanoma oncogene discovery. <b>2009</b> , 23, 397-414, vii	21
2087	Cancer genome sequencing: a review. <b>2009</b> , 18, R163-8	154
2086	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. <b>2009</b> , 27, 4150-4	752
2085	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. <b>2009</b> , 27, 5743-50	464
2084	Diagnostic and prognostic markers in gliomas. <b>2009</b> , 21, 537-42	38
2083	Combining drugs and radiotherapy: from the bench to the bedside. <b>2009</b> , 22, 625-32	16
2082	Classification and management of anaplastic gliomas. <b>2009</b> , 22, 650-6	10
2081	Current Opinion in Neurology. Current world literature. <b>2009</b> , 22, 681-92	
2080	Treatment of recurrent high-grade gliomas. <b>2009</b> , 22, 657-64	22
2079	Current world literature. <b>2009</b> , 21, 541-9	
2078	Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. <b>2009</b> , 22, 619-24	8
2077	Sequence-based advances in the definition of cancer-associated gene mutations. <b>2009</b> , 21, 47-52	9
2076	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. <b>2009</b> , 2009, 185-186	2
2075	Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. <b>2009</b> , 114, 1987-98	35
2074	Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. <b>2009</b> , 4, 787-91	25
2073	Epigenetic modulation in hematologic malignancies: challenges and progress. <b>2009</b> , 7 Suppl 8, S1-12; quiz S14-6	7
2072	Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. <b>2009</b> , 68, 1319-25	125

2071	Dephosphorylation of beta-arrestin 1 in glioblastomas. <b>2009</b> , 68, 535-41	12
2070	Translating the cancer genome into clinically useful tools and strategies. <b>2009</b> , 2, 426-9	11
2069	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. <b>2010</b> , 95, 1668-74	155
2068	Intrathecal nucleic acid injections to treat neuropathic pain. <b>2010</b> , 66, N18	
2067	CT alone may be inadequate for detecting occult spinal injuries. <b>2010</b> , 66, N23-4	
2066	Expression of PROX1 is a common feature of high-grade malignant astrocytic gliomas. <b>2010</b> , 69, 129-38	40
2065	Key factors contributing to the success of clinician investigators: converting K08 and K23 to R01 awards. <b>2010</b> , 66, N14-5	2
2064	Thoughts on consciousness. <b>2010</b> , 66, N22-3	
2063	A T cell-orchestrated immune response in the adult dorsal spinal cord as a cause of neuropathic pain-like hypersensitivity after peripheral nerve damage: a door to novel therapies?. <b>2010</b> , 66, N24-5	4
2062	Glioma diagnosis: immunohistochemistry and beyond. <b>2010</b> , 17, 187-201	46
2061	Riding the waves: intrinsic theta generation in the hippocampus. <b>2010</b> , 66, N15-6	1
2060	IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate. <b>2010</b> , 66, N20-1	10
2059	O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. <b>2010</b> , 67, 1681-91	30
2058	Regeneration of neuromuscular synapses: action of microRNA-206. <b>2010</b> , 66, N19-20	5
2057	Low- and High-Grade Glioma. <b>2010</b> , 7-23	
2056	[The role of chemotherapy in pediatric medulloblastoma]. <b>2010</b> , 54, 145-52	1
2055	Human variation databases. <b>2010</b> , 2010, baq015	17
2054	Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. <b>2010</b> , 116, 2122-6	288

2053	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. <b>2010</b> , 115, 2749-54		176
2052	The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. <b>2010</b> , 116, 2779-82		105
2051	Forcing tumor stem cells to an end. <b>2010</b> , 66, N17-8		
2050	Akt and autophagy cooperate to promote survival of drug-resistant glioma. <b>2010</b> , 3, ra81		225
2049	Role of RAS in the regulation of PI 3-kinase. <b>2010</b> , 346, 143-69		83
2048	Chronotherapy and the molecular clock: Clinical implications in oncology. <b>2010</b> , 62, 979-1001		118
2047	The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. <i>Science</i> , <b>2010</b> , 330, 1340-4	33:3	894
2046	Emerging roles for WNK kinases in cancer. <b>2010</b> , 67, 1265-76		68
2045	[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. <b>2010</b> , 81, 928-30, 932-5		1
2044	Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. <b>2010</b> , 119, 509-11		88
2043	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. <b>2010</b> , 119, 487-94		224
2042	Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. <b>2010</b> , 119, 501-7		101
2041	Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. <b>2010</b> , 120, 261-7		40
2040	Molecular diagnostics of gliomas: state of the art. <b>2010</b> , 120, 567-84		208
2039	MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. <b>2010</b> , 120, 731-43		47
2038	Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. <b>2010</b> , 120, 719-29		233
2037	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <b>2010</b> , 120, 707-18		596
2036	alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. <b>2010</b> , 15, 782-94		46

2035	The metabolic switch and its regulation in cancer cells. <b>2010</b> , 53, 942-58	13
2034	Neuroinformatics in clinical and translational medicine--novel approaches. <b>2010</b> , 8, 207-12	1
2033	Beryllium sulfate induces p21 CDKN1A expression and a senescence-like cell cycle arrest in susceptible cancer cell types. <b>2010</b> , 23, 1061-73	6
2032	A survey of glioblastoma genomic amplifications and deletions. <b>2010</b> , 96, 169-79	100
2031	A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. <b>2010</b> , 99, 165-76	44
2030	Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. <b>2010</b> , 99, 209-15	59
2029	CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples. <b>2010</b> , 100, 43-9	26
2028	Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. <b>2010</b> , 99, 155-63	36
2027	Meningiomas and neurofibromatosis. <b>2010</b> , 99, 341-7	79
2026	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. <b>2010</b> , 9, 717-26	216
2025	Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families. <b>2010</b> , 693, 32-45	44
2024	Why do we need a new paradigm in radiobiology?. <b>2010</b> , 687, 3-6	8
2023	The DNA methylome of glioblastoma multiforme. <b>2010</b> , 39, 40-6	45
2022	Statistical method on nonrandom clustering with application to somatic mutations in cancer. <b>2010</b> , 11, 11	46
2021	Extending pathways and processes using molecular interaction networks to analyse cancer genome data. <b>2010</b> , 11, 597	34
2020	Extracting consistent knowledge from highly inconsistent cancer gene data sources. <b>2010</b> , 11, 76	41
2019	Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. <b>2010</b> , 60, 166-93	950
2018	Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. <b>2010</b> , 10, 202	93



2017	A simple algebraic cancer equation: calculating how cancers may arise with normal mutation rates. <b>2010</b> , 10, 3	40
2016	MRP3: a molecular target for human glioblastoma multiforme immunotherapy. <b>2010</b> , 10, 468	35
2015	Notch signaling in glioblastoma: a developmental drug target?. <b>2010</b> , 8, 72	60
2014	Cancer as a metabolic disease. <b>2010</b> , 7, 7	368
2013	Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. <b>2010</b> , 4, 163	70
2012	An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. <b>2010</b> , 4, 67	48
2011	Mechanisms of chromosomal instability. <b>2010</b> , 20, R285-95	368
2010	MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?. <b>2010</b> , 1805, 72-86	35
2009	Tumor heterogeneity: causes and consequences. <b>2010</b> , 1805, 105-17	750
2008	Hedgehog beyond medulloblastoma and basal cell carcinoma. <b>2010</b> , 1805, 181-208	246
2007	Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma. <b>2010</b> , 80, 1517-27	41
2006	Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. <b>2010</b> , 1352, 200-7	28
2005	Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. <b>2010</b> , 202, 67-9	17
2004	IDH1 mutations in gliomas: when an enzyme loses its grip. <b>2010</b> , 17, 7-9	56
2003	IDH1 and IDH2: not your typical oncogenes. <b>2010</b> , 17, 215-6	60
2002	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. <b>2010</b> , 17, 510-22	1754
2001	PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. <b>2010</b> , 17, 497-509	189
2000	Integrative genomic profiling of human prostate cancer. <b>2010</b> , 18, 11-22	2666

1999	Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. <b>2010</b> , 18, 619-29	183
1998	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. <b>2010</b> , 18, 553-67	1933
1997	The Aurora A F31I polymorphism is not a risk factor for glioblastoma. <b>2010</b> , 74, 144-6	3
1996	The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. <b>2010</b> , 116, 282-5	21
1995	Mitochondrial dysfunction in neurodegenerative diseases and cancer. <b>2010</b> , 51, 391-405	151
1994	Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. <b>2010</b> , 49, 509-17	20
1993	Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. <b>2010</b> , 116, 4495-501	31
1992	Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. <b>2010</b> , 52, 1690-701	51
1991	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. <b>2010</b> , 31, 264-71	38
1990	Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. <b>2010</b> , 31, E1186-99	84
1989	COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. <b>2010</b> , 31, 1360-5	34
1988	Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation. <b>2010</b> , 127, 246-7	1
1987	IDH1 and IDH2 hotspot mutations are not found in canine glioma. <b>2010</b> , 127, 245-6	26
1986	The evolutionary mechanism of cancer. <b>2010</b> , 109, 1072-84	62
1985	The A2A adenosine receptor rescues neuritogenesis impaired by p53 blockage via KIF2A, a kinesin family member. <b>2010</b> , 70, 604-21	19
1984	Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. <b>2010</b> , 34, 1091-3	15
1983	Mutational analysis of IDH1 codon 132 in non-Hodgkin lymphomas. <b>2010</b> , 34, e313-4	1
1982	Deregulated signalling networks in human brain tumours. <b>2010</b> , 1804, 476-83	28

1981	Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design. <b>2010</b> , 1804, 533-40	12
1980	Design, synthesis and qualitative structure-activity evaluations of novel hexahydropyrano[3,2-c][1,2]diazepin-3(4H)-one and tetrahydropyrano[3,2-b]pyrrol-2(1H)-one derivatives as anticancer agents. <b>2010</b> , 45, 4615-21	9
1979	The (r)evolution of cancer genetics. <b>2010</b> , 8, 74	11
1978	Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. <b>2010</b> , 4, 591-602	41
1977	In silico models of cancer. <b>2010</b> , 2, 438-459	81
1976	Does massively parallel DNA resequencing signify the end of histopathology as we know it?. <b>2010</b> , 220, 307-15	40
1975	Our changing view of the genomic landscape of cancer. <b>2010</b> , 220, 231-43	64
1974	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. <b>2010</b> , 221, 49-56	485
1973	Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. <b>2010</b> , 221, 411-24	34
1972	Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. <b>2010</b> , 55, 1066-71	20
1971	Mitochondrial diseases and the role of the yeast models. <b>2010</b> , 10, 1006-22	33
1970	Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. <b>2010</b> , 29, 2441-8	111
1969	Genetic determinants at the interface of cancer and neurodegenerative disease. <b>2010</b> , 29, 3453-64	79
1968	The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. <b>2010</b> , 29, 6138-48	22
1967	Cancer-associated IDH mutations: biomarker and therapeutic opportunities. <b>2010</b> , 29, 6409-17	221
1966	Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. <b>2010</b> , 102, 243-8	8
1965	E17K substitution in AKT1 in prostate cancer. <b>2010</b> , 102, 1491-4	27
1964	Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. <b>2010</b> , 103, 827-36	48

1963	Mutated genes, pathways and processes in tumours. <b>2010</b> , 11, 805-10	27
1962	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. <b>2010</b> , 24, 1283-9	72
1961	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. <b>2010</b> , 24, 1302-9	266
1960	Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. <b>2010</b> , 24, 909-13	83
1959	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. <b>2010</b> , 24, 1128-38	435
1958	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. <b>2010</b> , 24, 1146-51	160
1957	A comprehensive catalogue of somatic mutations from a human cancer genome. <b>2010</b> , 463, 191-6	1303
1956	Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. <b>2010</b> , 463, 360-3	927
1955	International network of cancer genome projects. <b>2010</b> , 464, 993-8	1613
1954	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. <b>2010</b> , 466, 632-6	283
1953	Diverse somatic mutation patterns and pathway alterations in human cancers. <b>2010</b> , 466, 869-73	1003
1952	Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. <b>2010</b> , 10, 310-23	36
1951	Genomics boosts brain-cancer work. <b>2010</b> , 463, 278	9
1950	Big science: The cancer genome challenge. <b>2010</b> , 464, 972-4	73
1949	Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. <b>2010</b> , 42, 77-82	280
1948	A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. <b>2010</b> , 16, 671-7	122
1947	Targeting metabolic transformation for cancer therapy. <b>2010</b> , 10, 267-77	836
1946	Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. <b>2010</b> , 10, 319-31	578

1945	Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. <b>2010</b> , 10, 842-57	529
1944	Advances in understanding cancer genomes through second-generation sequencing. <b>2010</b> , 11, 685-96	890
1943	Unleashing formins to remodel the actin and microtubule cytoskeletons. <b>2010</b> , 11, 62-74	386
1942	Genomic instability--an evolving hallmark of cancer. <b>2010</b> , 11, 220-8	1393
1941	The emerging mechanisms of isoform-specific PI3K signalling. <b>2010</b> , 11, 329-41	1225
1940	New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. <b>2010</b> , 1210, 1-7	9
1939	Array-based genomics in glioma research. <b>2010</b> , 20, 28-38	12
1938	PCR- and restriction endonuclease-based detection of IDH1 mutations. <b>2010</b> , 20, 298-300	53
1937	Recent insights into PDGF-induced gliomagenesis. <b>2010</b> , 20, 527-38	36
1936	Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. <b>2010</b> , 20, 245-54	410
1935	Glioma pathophysiology: insights emerging from proteomics. <b>2010</b> , 20, 691-703	49
1934	Intratumoral patterns of genomic imbalance in glioblastomas. <b>2010</b> , 20, 936-44	52
1933	Gliomas in adults. <b>2010</b> , 107, 799-807; quiz 808	42
1932	Automated network analysis identifies core pathways in glioblastoma. <b>2010</b> , 5, e8918	268
1931	Increasing alternative promoter repertoires is positively associated with differential expression and disease susceptibility. <b>2010</b> , 5, e9482	13
1930	Second generation sequencing of the mesothelioma tumor genome. <b>2010</b> , 5, e10612	59
1929	Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. <b>2010</b> , 5, e10767	51
1928	Specific visualization of glioma cells in living low-grade tumor tissue. <b>2010</b> , 5, e11323	27

1927	Frequent MAGE mutations in human melanoma. <b>2010</b> , 5, e12773	22
1926	Improving cancer classification accuracy using gene pairs. <b>2010</b> , 5, e14305	37
1925	Decreasing glioma recurrence through adjuvant cancer stem cell inhibition. <b>2010</b> , 4, 157-62	10
1924	Phosphoinositide 3-Kinases. <b>2010</b> , 1049-1060	
1923	Temozolomide in malignant glioma. <b>2010</b> , 3, 139-46	18
1922	[Hopes and challenges in biomedical research]. <b>2010</b> , 26, 3-4	
1921	Targeting Ras for Anticancer Drug Discovery. <b>2010</b> , 2837-2857	
1920	Génomique des leucémies aiguës myéloblastiques de l'adulte. <b>2010</b> , 16, 9-15	
1919	Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. <b>2010</b> , 28, 3061-8	468
1918	Familial aggregation of glioma: a pooled analysis. <b>2010</b> , 172, 1099-107	39
1917	Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease. <b>2010</b> , 84, 7675-82	8
1916	Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. <b>2010</b> , 16, 4155-64	75
1915	The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. <b>2010</b> , 16, 6060-70	128
1914	Protein microarrays for cancer diagnostics and therapy. <b>2010</b> , 19, 247-54	13
1913	Malignant astrocytomas: a system disease. <b>2010</b> , 67, 353-5	39
1912	Prognostic markers in gliomas. <b>2010</b> , 6, 733-9	15
1911	A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. <b>2010</b> , 16, 3368-77	116
1910	Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. <b>2010</b> , 12, 1205-19	68

1909	A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. <b>2010</b> , 70, 2158-64	67
1908	Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. <b>2010</b> , 17, R287-304	56
1907	Clinical implications of the cancer genome. <b>2010</b> , 28, 5219-28	156
1906	IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. <i>Science</i> , <b>2010</b> , 330, 336	33-3 152
1905	Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. <b>2010</b> , 24, 2612-9	25
1904	CpG island hypermethylation in human astrocytomas. <b>2010</b> , 70, 2718-27	111
1903	Genetic risk profiles identify different molecular etiologies for glioma. <b>2010</b> , 16, 5252-9	48
1902	Separating the wheat from the chaff: the search for truly informative biomarkers. <b>2010</b> , 74, 1848-9	1
1901	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. <b>2010</b> , 16, 5972-80	98
1900	Molecular evolutionary analysis of cancer cell lines. <b>2010</b> , 9, 279-91	8
1899	Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis. <b>2010</b> , 38, 123-30	10
1898	Inhibition of the PI3K pathway: hope we can believe in?. <b>2010</b> , 16, 3094-9	34
1897	Knowledge-based data analysis comes of age. <b>2010</b> , 11, 30-9	14
1896	Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. <b>2010</b> , 70, 3228-38	223
1895	A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. <b>2010</b> , 112, 997-1004	103
1894	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. <b>2010</b> , 70, 512-9	201
1893	Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. <b>2010</b> , 70, 1689-99	60
1892	Roles of fibroblast growth factor receptors in carcinogenesis. <b>2010</b> , 8, 1439-52	223

1891	Immunohistochemical characterization of canine neuroepithelial tumors. <b>2010</b> , 47, 741-50	50
1890	On getting there from here. <i>Science</i> , <b>2010</b> , 330, 1338-9	33-3 85
1889	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. <b>2010</b> , 107, 6912-7	91
1888	Error-prone translesion synthesis mediates acquired chemoresistance. <b>2010</b> , 107, 20792-7	158
1887	Computational tools for the interactive exploration of proteomic and structural data. <b>2010</b> , 9, 1703-15	7
1886	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. <b>2010</b> , 31, 208-15	65
1885	PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. <b>2010</b> , 12, 967-75	29
1884	Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?. <b>2010</b> , 10, 839-53	55
1883	Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. <b>2010</b> , 9, 1234-43	31
1882	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <b>2010</b> , 28, 2348-55	599
1881	Oligodendroglioma cell lines containing t(1;19)(q10;p10). <b>2010</b> , 12, 745-55	65
1880	Biomedical Informatics for Cancer Research. <b>2010</b> ,	8
1879	Interaction between 5 genetic variants and allergy in glioma risk. <b>2010</b> , 171, 1165-73	44
1878	Analysis of next-generation genomic data in cancer: accomplishments and challenges. <b>2010</b> , 19, R188-96	102
1877	Update on molecular findings, management and outcome in low-grade gliomas. <b>2010</b> , 6, 695-701	105
1876	Regulatory subunits of class IA PI3K. <b>2010</b> , 346, 225-44	29
1875	Neuro-oncology: Genetic variation in pediatric and adult brain tumors. <b>2010</b> , 6, 653-4	4
1874	Neurofibromatosis type 1: diagnosis and recent advances. <b>2010</b> , 4, 307-22	29



1873	Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. <b>2010</b> , 28, E8	80
1872	Genetics of medulloblastoma: clues for novel therapies. <b>2010</b> , 10, 811-23	10
1871	Population genetics meets cancer genomics. <b>2010</b> , 107, 18241-2	4
1870	Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes. <b>2010</b> , 38, D670-5	23
1869	Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. <b>2010</b> , 107, 20780-5	71
1868	IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?. <b>2010</b> , 15, 196-9	43
1867	Systematic interpretation of comutated genes in large-scale cancer mutation profiles. <b>2010</b> , 9, 2186-95	11
1866	Malignant Gliomas in Adults. <b>2010</b> , 36, 99-120	5
1865	Advances in translational bioinformatics: computational approaches for the hunting of disease genes. <b>2010</b> , 11, 96-110	66
1864	Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. <b>2010</b> , 107, 1576-81	100
1863	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. <b>2010</b> , 116, 4086-94	152
1862	Systems Biology in Drug Discovery: Using Predictive Biomedicine to Guide Development Choices for Novel Agents in Cancer. <b>2010</b> , 399-414	1
1861	The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. <b>2010</b> , 24, 683-95	109
1860	Oncogenic mutations of PIK3CA in human cancers. <b>2010</b> , 347, 21-41	164
1859	Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. <b>2010</b> , 70, 5923-30	554
1858	Comprehensive mapping of the human kinome to epidermal growth factor receptor signaling. <b>2010</b> , 285, 21134-42	28
1857	Potential role of PI3K inhibitors in the treatment of breast cancer. <b>2010</b> , 6, 1251-63	7
1856	Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. <b>2010</b> , 70, 3557-65	54

1855	Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. <b>2010</b> , 285, 19647-59	35
1854	Cell selection as driving force in lung and colon carcinogenesis. <b>2010</b> , 70, 6797-803	29
1853	Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. <b>2010</b> , 107, 15547-52	119
1852	Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. <b>2010</b> , 28, 2467-74	87
1851	Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. <b>2010</b> , 70, 859-62	312
1850	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. <b>2010</b> , 207, 339-44	564
1849	Metabolism and the leukemic stem cell. <b>2010</b> , 207, 677-80	62
1848	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. <b>2010</b> , 28, E6	40
1847	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. <b>2010</b> , 75, 1560-6	402
1846	PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. <b>2010</b> , 12, 941-55	50
1845	Ultra-deep sequencing of a human ultraconserved region reveals somatic and constitutional genomic instability. <b>2010</b> , 8, e1000275	21
1844	The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. <b>2010</b> , 9, 2618-26	32
1843	Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. <b>2010</b> , 6, e1000899	291
1842	HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. <b>2010</b> , 12, 956-66	11
1841	The Salmonella mutagenicity assay: the stethoscope of genetic toxicology for the 21st century. <b>2010</b> , 118, 1515-22	101
1840	Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). <b>2010</b> , 6, e1000792	64
1839	Targeting A20 decreases glioma stem cell survival and tumor growth. <b>2010</b> , 8, e1000319	103
1838	Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. <b>2010</b> , 163, 747-55	69

1837	IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. <b>2010</b> , 24, 2120-2	31
1836	Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. <b>2010</b> , 70, 9730-41	43
1835	Targeted deep resequencing of the human cancer genome using next-generation technologies. <b>2010</b> , 27, 135-58	10
1834	The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. <b>2010</b> , 9, 1451-2	27
1833	Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). <b>2010</b> , 10, 582-7	70
1832	Emerging role of paxillin-PKL in regulation of cell adhesion, polarity and migration. <b>2010</b> , 4, 342-7	12
1831	From man to mouse and back again: advances in defining tumor AKTivities in vivo. <b>2010</b> , 3, 705-20	13
1830	Creation and validation of a new animal model of intracranial aneurysms. <b>2010</b> , 66, N16-7	
1829	p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. <b>2010</b> , 9, 1411-20	53
1828	Viewing cancer genes from co-evolving gene modules. <b>2010</b> , 26, 919-24	2
1827	Genome-wide association studies: a powerful tool for neurogenomics. <b>2010</b> , 28, E2	6
1826	[Personalized therapy of gastrointestinal cancers--possibilities and limitations]. <b>2010</b> , 135, 1687-91	
1825	[Genetic and molecular abnormalities of glioblastomas (GBM)]. <b>2010</b> , 97, 1389-407	4
1824	The missing zinc: p53 misfolding and cancer. <b>2010</b> , 2, 442-9	89
1823	Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. <b>2010</b> , 28, E4	12
1822	The regulation of class IA PI 3-kinases by inter-subunit interactions. <b>2010</b> , 346, 87-114	63
1821	Establishment of a human glioblastoma stemlike brainstem rodent tumor model. <b>2010</b> , 6, 92-7	15
1820	Individual genomes on the horizon. <b>2010</b> , 362, 1235-6	38

1819	Diagnostic and prognostic molecular markers in common adult gliomas. <b>2010</b> , 10, 637-49	1
1818	Metabolic syndromes and malignant transformation: where the twain shall meet. <b>2010</b> , 2, 54p50	2
1817	IDH1 mutant structures reveal a mechanism of dominant inhibition. <b>2010</b> , 20, 1279-81	22
1816	Functional genomics to explore cancer cell vulnerabilities. <b>2010</b> , 28, E5	4
1815	Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. <b>2010</b> , 95, 1274-8	100
1814	Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas. <b>2010</b> , 95, 1469-72	23
1813	Phosphatidylinositol 3-kinase: the oncoprotein. <b>2010</b> , 347, 79-104	76
1812	Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors. <b>2010</b> , 17, 234-53	15
1811	[Advances in adults' gliomas biology, imaging and treatment]. <b>2010</b> , 97, 17-36	12
1810	PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. <b>2010</b> , 70, 5457-64	189
1809	2010 Keystone Symposium: Metabolism and Cancer Progression. <b>2010</b> , 6, 893-5	2
1808	IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications. <b>2010</b> , 95, 1623-7	18
1807	Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. <b>2010</b> , 20, 425-48	14
1806	Mutation des gènes IDH1/IDH2 : un nouveau marqueur pronostique dans les gliomes. <b>2010</b> , 166, S22-S23	1
1805	Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. <b>2010</b> , 6, 1591-601	42
1804	A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. <b>2010</b> , 12, 499-505	28
1803	Glioblastoma therapy: going beyond Hercules Columns. <b>2010</b> , 10, 507-14	40
1802	Nontargeted elucidation of metabolic pathways using stable-isotope tracers and mass spectrometry. <b>2010</b> , 82, 6621-8	96

1801 s-RT-MELT: a novel technology for mutation screening. **2010**, 653, 207-19

1800 Glioma stem cell signaling: therapeutic opportunities and challenges. **2010**, 10, 709-22 30

1799 Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. **2010**, 6, 1407-14 20

1798 Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. **2010**, 12, 487-92 66

1797 PROBING CANCER SIGNALING WITH RESONANT WAVEGUIDE GRATING BIOSENSORS. **2010**, 5, 1237-1248 22

1796 Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. **2010**, 70, 277-308 105

1795 Pathology and Classification of Tumors of the Nervous System. **2010**, 3-75 3

1794 Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. **2010**, 6, 369 90

1793 Whole genome sequencing. **2010**, 628, 215-26 116

1792 A window into third-generation sequencing. **2010**, 19, R227-40 628

1791 Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. **2010**, 9, 135 203

1790 Personalized therapies in the cancer "omics" era. **2010**, 9, 202 39

1789 An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. **2010**, 9, 234 34

1788 Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. **2010**, 7, 33 173

1787 IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. **2010**, 28, 3636-43 615

1786 Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes. **2010**, 12, 418-24 47

1785 mTOR signaling in glioblastoma: lessons learned from bench to bedside. **2010**, 12, 882-9 124

1784 Accumulation of driver and passenger mutations during tumor progression. **2010**, 107, 18545-50 574

1783	Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. <b>2010</b> , 14, 163-9	24
1782	Molecular networks for the study of TCM pharmacology. <b>2010</b> , 11, 417-30	164
1781	Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. <b>2010</b> , 23, 327-35	174
1780	Ras history: The saga continues. <b>2010</b> , 1, 2-27	457
1779	Dysfunctional gene/protein networks in hepatitis C virus-induced hepatocellular cirrhosis and carcinoma. <b>2010</b> ,	3
1778	Mutational heterogeneity in human cancers: origin and consequences. <b>2010</b> , 5, 51-75	172
1777	Mitochondrially targeted anti-cancer agents. <b>2010</b> , 10, 670-81	100
1776	IDH mutations in glioma and acute myeloid leukemia. <b>2010</b> , 16, 387-97	274
1775	[Glioblastoma: clinical, radiological and biological prognostic factors]. <b>2010</b> , 56, 467-76	7
1774	[Classification of glioblastoma and genome profiling]. <b>2010</b> , 56, 464-6	
1773	[Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment]. <b>2010</b> , 56, 441-8	4
1772	TNFalpha induced oxidative stress dependent Akt signaling affects actin cytoskeletal organization in glioma cells. <b>2010</b> , 56, 194-201	22
1771	Expectations, validity, and reality in omics. <b>2010</b> , 63, 945-9	44
1770	Simplistic pathways or complex networks?. <b>2010</b> , 20, 15-22	37
1769	Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. <b>2010</b> , 20, 324-9	94
1768	Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. <b>2010</b> , 20, 336-41	4
1767	Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. <b>2010</b> , 13, 16-28	183
1766	Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. <b>2010</b> , 46, 170-9	32

1765	Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. <b>2010</b> , 46, 2166-77	62
1764	Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. <b>2010</b> , 393, 555-9	112
1763	Glioma-derived mutations in IDH: from mechanism to potential therapy. <b>2010</b> , 397, 127-30	39
1762	IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. <b>2010</b> , 402, 378-83	36
1761	Unveiling the role of network and systems biology in drug discovery. <b>2010</b> , 31, 115-23	281
1760	Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. <b>2010</b> , 22, 105-12	37
1759	The plasticity of the mammalian transcriptome. <b>2010</b> , 95, 1-6	53
1758	Next generation sequencing in research and diagnostics of ocular birth defects. <b>2010</b> , 100, 184-92	27
1757	Microfluidic isolation and transcriptome analysis of serum microvesicles. <b>2010</b> , 10, 505-11	377
1756	Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. <b>2010</b> , 70, 8981-7	380
1755	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. <b>2010</b> , 74, 1886-90	198
1754	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. <i>Science</i> , <b>2010</b> , 330, 228-31	333 915
1753	Brain tumor stem cells: the cancer stem cell hypothesis writ large. <b>2010</b> , 4, 420-30	104
1752	Genome-wide association studies of cancer predisposition. <b>2010</b> , 24, 973-96	33
1751	Practical molecular diagnostics in neuropathology: making a tough job a little easier. <b>2010</b> , 27, 105-13	17
1750	Oligodendroglial tumors: diagnostic and molecular pathology. <b>2010</b> , 27, 136-45	13
1749	Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. <b>2010</b> , 362, 369-70	240
1748	A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. <b>2010</b> , 12, 750-6	47

1747	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. <b>2010</b> , 102, 932-41	372
1746	Molecularly Targeted Therapies for Astrocytomas. <b>2010</b> , 231-265	1
1745	Origin of Cancers. <b>2010</b> ,	1
1744	Waiting Time Models of Cancer Progression. <b>2010</b> , 17, 115-135	18
1743	An Omics Perspective on Cancer Research. <b>2010</b> ,	9
1742	Molecularly Targeted Therapy for Childhood Cancer. <b>2010</b> ,	1
1741	Wilms tumor in a child with L-2-hydroxyglutaric aciduria. <b>2010</b> , 13, 408-11	20
1740	Systems Biology and Systems Medicine. <b>2010</b> , 131-141	1
1739	Genomic Evaluation of Brain Tumors and Gliomas. <b>2010</b> , 522-531	
1738	Kinases and Cancer. 1-74	
1737	mTOR Pathway and mTOR Inhibitors in Cancer Therapy. <b>2010</b> ,	2
1736	Modern Molecular Biology. <b>2010</b> ,	2
1735	Identification of novel SNPs by next-generation sequencing of the genomic region containing the APC gene in colorectal cancer patients in China. <b>2010</b> , 14, 315-25	7
1734	The expression and significance of IDH1 and p53 in osteosarcoma. <b>2010</b> , 29, 43	23
1733	Patient-oriented gene set analysis for cancer mutation data. <b>2010</b> , 11, R112	54
1732	Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. <b>2010</b> , 11, R114	32
1731	A human functional protein interaction network and its application to cancer data analysis. <b>2010</b> , 11, R53	453
1730	Translational Medicine: Application of Omics for Drug Target Discovery and Validation. <b>2010</b> , 235-247	3



1729	Cancer genomics identifies determinants of tumor biology. <b>2010</b> , 11, 211	14
1728	2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas. <b>2010</b> , 10, 487-9	8
1727	Correlation between IDH2 mutations and disease status in acute myeloid leukemia. <b>2010</b> , 51, 2157-8	
1726	Somatic mutation of PIK3R1 gene is rare in common human cancers. <b>2010</b> , 49, 125-7	5
1725	Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. <b>2010</b> , 26, i237-45	537
1724	D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. <b>2010</b> , 107, 14321-6	165
1723	Synthesis and evaluation of a near-infrared fluorescent non-peptidic bivalent integrin alpha(v)beta(3) antagonist for cancer imaging. <b>2010</b> , 21, 270-8	22
1722	Investigating microRNA-transcription factor mediated regulatory network in glioblastoma. <b>2010</b> ,	1
1721	PI3K: from the bench to the clinic and back. <b>2010</b> , 347, 1-19	57
1720	Structural effects of oncogenic PI3K mutations. <b>2010</b> , 347, 43-53	18
1719	NF-kappaB and STAT3 signaling in glioma: targets for future therapies. <b>2010</b> , 10, 575-86	103
1718	A pathway-based classification of human breast cancer. <b>2010</b> , 107, 6994-9	258
1717	Mutations in CIC and FUBP1 contribute to human oligodendroglioma. <i>Science</i> , <b>2011</b> , 333, 1453-5	33.3 399
1716	New targeted therapies for renal cell carcinoma. <b>2011</b> , 20, 933-45	1
1715	Pathway inhibition: emerging molecular targets for treating glioblastoma. <b>2011</b> , 13, 566-79	104
1714	Gene-protein correlation in single cells. <b>2011</b> , 13, 880-5	3
1713	Fibroblast growth factors and their receptors in cancer. <b>2011</b> , 437, 199-213	404
1712	Biology, genetics and imaging of glial cell tumours. <b>2011</b> , 84 Spec No 2, S90-106	45

1711	An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. <b>2011</b> , 1, 442-56	258
1710	Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. <b>2011</b> , 13, 634-47	44
1709	Algorithms for detecting significantly mutated pathways in cancer. <b>2011</b> , 18, 507-22	333
1708	Translational proteomics: what can you do for true patients?. <b>2011</b> , 10, 101-4	3
1707	Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. <b>2011</b> , 7, 486	67
1706	Mutant proteins as cancer-specific biomarkers. <b>2011</b> , 108, 2444-9	136
1705	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. <b>2011</b> , 108, 19024-9	81
1704	A comprehensive statistical model for cell signaling. <b>2011</b> , 8, 592-606	9
1703	Metabolism of glioma and IDH1/IDH2 mutations. <b>2011</b> , 167, 699-703	8
1702	Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. <b>2011</b> , 25, 2436-52	487
1701	Biomarqueurs pronostiques et facteurs prédictifs de la réponse au traitement dans les gliomes de l'adulte. <b>2011</b> , 2, 64-70	1
1700	Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. <b>2011</b> , 167, 683-90	22
1699	Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. <b>2011</b> , 13, 220-32	26
1698	Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. <b>2011</b> , 13, 81-97	570
1697	Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinositide-3-kinase. <b>2011</b> , 51, 273-9	4
1696	DNA secondary structures and epigenetic determinants of cancer genome evolution. <b>2011</b> , 18, 950-5	169
1695	Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. <b>2011</b> , 25, 1555-63	36
1694	Childhood brain tumors: epidemiology, current management and future directions. <b>2011</b> , 7, 495-506	94

1693	Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines. <b>2011</b> , 6, e21097	27
1692	Experimental and Applied Immunotherapy. <b>2011</b> ,	
1691	Spatial structure increases the waiting time for cancer. <b>2011</b> , 13,	63
1690	A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of HIF-1 $\alpha$ . <b>2011</b> , 50, 4804-12	81
1689	Molecular Classification of Gliomas. <b>2011</b> , 9-19	
1688	Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. <b>2011</b> , 7, e1002037	126
1687	[OMICS and biomarkers of glial tumors]. <b>2011</b> , 167, 691-8	2
1686	The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. <b>2011</b> , 17, 486-494	41
1685	Developing therapeutic microRNAs for cancer. <b>2011</b> , 18, 1121-6	253
1684	The genetic landscape of the childhood cancer medulloblastoma. <i>Science</i> , <b>2011</b> , 331, 435-9	33-3 576
1683	Integration and analysis of genome-scale data from gliomas. <b>2011</b> , 7, 439-50	83
1682	Targeting cancer metabolism: a therapeutic window opens. <b>2011</b> , 10, 671-84	1018
1681	Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. <b>2011</b> , 30, 76	23
1680	Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control. <b>2011</b> , 7, 1158-66	8
1679	Phosphoinositide 3-kinase in Health and Disease. <b>2011</b> ,	
1678	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. <b>2011</b> , 43, 1256-61	392
1677	Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. <b>2011</b> , 108, 17087-92	211
1676	Low-grade gliomas in adults. <b>2011</b> , 115, 948-65	194

1675	Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. <b>2011</b> , 13, 1026-34	37
1674	Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. <b>2011</b> , 4, 59-70	8
1673	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. <b>2011</b> , 1, e7	11
1672	The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view. <b>2011</b> , 8, 015016	43
1671	Phosphoinositide 3-kinase in Health and Disease. <b>2011</b> ,	
1670	Integrating diverse genomic data using gene sets. <b>2011</b> , 12, R105	45
1669	Cancer Systems Biology, Bioinformatics and Medicine. <b>2011</b> ,	3
1668	Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. <b>2011</b> , 11, 1759-74	22
1667	Evolutionary mechanisms and diversity in cancer. <b>2011</b> , 112, 217-53	72
1666	PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. <b>2011</b> , 13, 492-503	45
1665	Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. <b>2011</b> , 178, 1395-402	102
1664	Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. <b>2011</b> , 179, 46-54	71
1663	NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas. <b>2011</b> , 179, 462-76	20
1662	Mosaic analysis with double markers reveals tumor cell of origin in glioma. <b>2011</b> , 146, 209-21	461
1661	An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. <b>2011</b> , 147, 370-81	571
1660	SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. <b>2011</b> , 21, 1062-76	63
1659	Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression. <b>2011</b> , 81, 233-42	26
1658	Survival of the fittest: metabolic adaptations in cancer. <b>2011</b> , 21, 59-66	20

1657	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. <b>2011</b> , 47, 802-8	33
1656	A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies. <b>2011</b> , 1812, 1380-4	12
1655	Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. <b>2011</b> , 406, 608-13	44
1654	Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. <b>2011</b> , 410, 218-23	13
1653	Exploring the genomes of cancer cells: progress and promise. <i>Science</i> , <b>2011</b> , 331, 1553-8	33-3 488
1652	Cancer cell metabolism. <b>2011</b> , 76, 299-311	104
1651	The inverted pyramid of biomarker-driven trials. <b>2011</b> , 8, 562-6	14
1650	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. <b>2011</b> , 76, 410-3	12
1649	Structure of lipid kinase p110 $\beta$ elucidates an unusual SH2-domain-mediated inhibitory mechanism. <b>2011</b> , 41, 567-78	134
1648	Molecular targeting of glioblastoma: Drug discovery and therapies. <b>2011</b> , 17, 301-312	99
1647	Structural and functional impact of cancer-related missense somatic mutations. <b>2011</b> , 413, 495-512	33
1646	Anticancer drugs targeting the mitochondrial electron transport chain. <b>2011</b> , 15, 2951-74	68
1645	Epigenetics, nervous system tumors, and cancer stem cells. <b>2011</b> , 3, 3525-56	5
1644	Virchow 2011 or how to ID(H) human glioblastoma. <b>2011</b> , 29, 4473-4	18
1643	A new disease-specific machine learning approach for the prediction of cancer-causing missense variants. <b>2011</b> , 98, 310-7	56
1642	TET family proteins and their role in stem cell differentiation and transformation. <b>2011</b> , 9, 193-204	183
1641	Metabolic regulation of hematopoietic stem cells in the hypoxic niche. <b>2011</b> , 9, 298-310	544
1640	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. <b>2011</b> , 12, 83-91	167

1639	Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. <b>2011</b> , 2, 180	765
1638	Will kinase inhibitors make it as glioblastoma drugs?. <b>2012</b> , 355, 135-69	18
1637	Reverse phase protein microarrays for clinical applications. <b>2011</b> , 785, 3-12	15
1636	The Role of IDH1 and IDH2 Mutations in Malignant Gliomas. <b>2011</b> , 47-52	
1635	The origins of cancer robustness and evolvability. <b>2011</b> , 3, 17-30	114
1634	Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma. <b>2011</b> , 4, 58-62	1
1633	Treatment of recurrent high-grade gliomas. <b>2011</b> , 8, 171-177	
1632	Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. <b>2011</b> , 4, re2	201
1631	Nuclear remodeling as a mechanism for genomic instability in cancer. <b>2011</b> , 112, 77-126	20
1630	Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. <b>2011</b> , 71, 7587-96	62
1629	Myelodysplastic/myeloproliferative neoplasms. <b>2011</b> , 28, 283-97	15
1628	Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. <b>2011</b> , 81, 623-30	169
1627	STATus and Context within the Mammalian Nervous System. <b>2011</b> , 17, 965-73	8
1626	Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. <b>2011</b> ,	1
1625	Role of the Centrosomal MARK4 Protein in Gliomagenesis. <b>2011</b> ,	
1624	Molecular Hallmarks of Gliomas. <b>2011</b> ,	2
1623	The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors. <b>2011</b> ,	1
1622	WNK2 (WNK lysine deficient protein kinase 2). <b>2011</b> ,	

1621	Integrated Network Analysis of Genetic and Epigenetic Factors in Glioblastoma Multiform. <b>2011,</b>	
1620	. <b>2011,</b>	22
1619	Glioblastoma multiforme stem cells. <b>2011,</b> 11, 930-58	20
1618	REPS2 (RALBP1 associated Eps domain containing 2). <b>2011,</b>	
1617	The Musashi1 RNA-Binding Protein: A Critical Regulator in Glioblastoma. <b>2011,</b>	
1616	Genetic Instability in Paediatric and Adult Brain Tumours. <b>2011,</b>	
1615	Molecular Pathways of Glioblastoma and Glioblastoma Stem Cells. <b>2011,</b>	
1614	Novel Therapeutic Venues for Glioblastoma: Novel Rising Preclinical Treatment Opportunities. <b>2011,</b>	
1613	Classification of Primary Brain Tumors: Molecular Aspects. <b>2011,</b>	
1612	Genetics and Biology of Glioblastoma Multiforme. <b>2011,</b>	2
1611	Metabolism and brain cancer. <b>2011,</b> 66 Suppl 1, 33-43	75
1610	Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. <b>2011,</b> 2011, 852970	21
1609	Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. <b>2011,</b> 4, 47	45
1608	Grand challenges in oncology. <b>2011,</b> 1, 26	
1607	Animal models to study cancer-initiating cells from glioblastoma. <b>2011,</b> 16, 2243-58	17
1606	Respiratory chain complex I is a mitochondrial tumor suppressor of oncogenic tumors. <b>2011,</b> 3, 315-25	33
1605	Emerging metabolic targets in cancer therapy. <b>2011,</b> 16, 1844-60	65
1604	Early events during neoplastic progression in Barrett's esophagus. <b>2010,</b> 9, 307-24	17

1603	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. <b>2011</b> , 6, e17948	228
1602	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. <b>2011</b> , 6, e16812	92
1601	Interactions between the Nse3 and Nse4 components of the SMC5-6 complex identify evolutionarily conserved interactions between MAGE and EID Families. <b>2011</b> , 6, e17270	36
1600	A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. <b>2011</b> , 6, e17649	95
1599	Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. <b>2011</b> , 6, e19868	53
1598	Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. <b>2011</b> , 6, e20090	51
1597	The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. <b>2011</b> , 6, e23332	76
1596	Genetics of the myeloproliferative neoplasms. <b>2011</b> , 18, 117-23	43
1595	Advances in ultra-high field MRI for the clinical management of patients with brain tumors. <b>2011</b> , 24, 605-15	29
1594	Next-generation sequencing: emerging lessons on the origins of human cancer. <b>2011</b> , 23, 62-8	31
1593	Genetic causes of glioma: new leads in the labyrinth. <b>2011</b> , 23, 643-7	25
1592	Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. <b>2011</b> , 24, 648-52	57
1591	Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism. <b>2011</b> , 70, 167-76	65
1590	Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. <b>2011</b> , 70, 715-23	82
1589	Extraventricular neurocytomas: a morphological and histogenetic consideration. A study of six cases. <b>2011</b> , 43, 327-34	22
1588	Advances in translational research in neuro-oncology. <b>2011</b> , 68, 303-8	4
1587	Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. <b>2011</b> , 1, 161	327
1586	Traveling waves of selective sweeps. <b>2011</b> , 21,	14



1585	A novel potent tumour promoter aberrantly overexpressed in most human cancers. <b>2011</b> , 1, 15	13
1584	Central nervous system. <b>2010</b> , 9, 193-210	28
1583	IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. <b>2011</b> , 26, 1479-85	21
1582	False discovery rates in somatic mutation studies of cancer. <b>2011</b> , 5,	6
1581	Development of a phylogenetic tree model to investigate the role of genetic mutations in endometrial tumors. <b>2011</b> , 25, 1447-54	28
1580	Human genetics and genomics a decade after the release of the draft sequence of the human genome. <b>2011</b> , 5, 577-622	65
1579	Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. <b>2011</b> , 5, 623-90	94
1578	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. <b>2011</b> , 9 Suppl 5, S1-32; quiz S33	195
1577	DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification. <b>2011</b> , 31, 29-37	22
1576	Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. <b>2011</b> , 37, 330-2	7
1575	Secondary anaplastic astrocytoma developing in a young adult with autoimmune lymphoproliferative syndrome (ALPS). <b>2011</b> , 37, 423-7	
1574	Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?—Implications for cancer immunotherapy by adoptive T cell transfer. <b>2011</b> , 73, 527-30	9
1573	Identification and genetic determination of an early life risk disposition for depressive disorder: Atypical stress-related behaviour in early childhood. <b>2011</b> , 63, 6-17	3
1572	High-resolution characterization of a hepatocellular carcinoma genome. <b>2011</b> , 43, 464-9	241
1571	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. <b>2011</b> , 17, 304-12	77
1570	Cancer genomics: from discovery science to personalized medicine. <b>2011</b> , 17, 297-303	415
1569	A close look at cancer. <b>2011</b> , 17, 262-5	7
1568	Metabolism unhinged: IDH mutations in cancer. <b>2011</b> , 17, 291-3	123

1567 Research Highlights. **2011**, 17, 294-295

1566 Regulation of cancer cell metabolism. **2011**, 11, 85-95 3403

1565 Nucleating actin for invasion. **2011**, 11, 177-87 192

1564 Otto Warburg's contributions to current concepts of cancer metabolism. **2011**, 11, 325-37 1912

1563 Human cancers express mutator phenotypes: origin, consequences and targeting. **2011**, 11, 450-7 291

1562 Variation in the mutation rate across mammalian genomes. **2011**, 12, 756-66 287

1561 Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. **2011**, 30, 978-89 46

1560 Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. **2011**, 30, 1341-50 32

1559 NF- $\kappa$ B addiction and its role in cancer: 'one size does not fit all'. **2011**, 30, 1615-30 371

1558 Regulation and function of TPL-2, an I $\kappa$ B kinase-regulated MAP kinase kinase kinase. **2011**, 21, 131-45 102

1557 Low prevalence of IDH1 gene mutation in childhood AML in Italy. **2011**, 25, 173-4 7

1556 IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. **2011**, 25, 178-81 20

1555 A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. **2011**, 25, 184-6 14

1554 The genomic complexity of primary human prostate cancer. **2011**, 470, 214-20 984

1553 Initial impact of the sequencing of the human genome. **2011**, 470, 187-97 750

1552 Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. **2011**, 58, 1167-72 12

1551 Molecular diagnostics in neuro-oncology. Introduction. **2011**, 21, 55-6

1550 The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. **2011**, 21, 74-87 126

1549	The use of global profiling in biomarker development for gliomas. <b>2011</b> , 21, 88-95	17
1548	Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. <b>2011</b> , 21, 564-74	44
1547	Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. <b>2011</b> , 21, 619-32	33
1546	Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. <b>2011</b> , 44, 84-91	80
1545	Structure-based systems biology for analyzing off-target binding. <b>2011</b> , 21, 189-99	116
1544	An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. <b>2011</b> , 38, 215-24	16
1543	Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. <b>2011</b> , 38, 243-53	59
1542	The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. <b>2011</b> , 38 Suppl 4, S11-20	15
1541	Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. <b>2011</b> , 317, 1476-89	42
1540	IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. <b>2011</b> , 91, 385-93	29
1539	Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. <b>2011</b> , 16, 1044-51	34
1538	Dissecting DNA hypermethylation in cancer. <b>2011</b> , 585, 2078-86	58
1537	Mitochondrial targeting of Etoposide succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. <b>2011</b> , 50, 1546-55	91
1536	Metabolic management of brain cancer. <b>2011</b> , 1807, 577-94	94
1535	SDH mutations in cancer. <b>2011</b> , 1807, 1432-43	257
1534	Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. <b>2011</b> , 1816, 199-208	12
1533	Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of $\alpha$ -ketoglutarate-dependent dioxygenases. <b>2011</b> , 19, 17-30	1919
1532	The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. <b>2011</b> , 19, 359-71	119

1531	Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. <b>2011</b> , 19, 305-16	212
1530	Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. <b>2011</b> , 20, 11-24	876
1529	Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. <b>2011</b> , 20, 400-13	199
1528	New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?. <b>2011</b> , 17, 6-11	17
1527	Pathways and Networks as Functional Descriptors for Human Disease and Drug Response Endpoints. <b>2011</b> , 415-442	2
1526	Translating tumor antigens into cancer vaccines. <b>2011</b> , 18, 23-34	148
1525	The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. <b>2011</b> , 12, 495-508	223
1524	PI3K and STAT3: a new alliance. <b>2011</b> , 1, 481-6	89
1523	Predictive and prognostic factors for gliomas. <b>2011</b> , 11, 781-9	49
1522	Molecular Pathogenesis. <b>2011</b> , 27-44	1
1521	Molecular pathogenesis of malignant glial tumors. <b>2011</b> , 39, 158-66	16
1520	Molecular Subtypes of Gliomas. <b>2011</b> , 25-29	
1519	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. <b>2011</b> , 43, 869-74	788
1518	What can exome sequencing do for you?. <b>2011</b> , 48, 580-9	263
1517	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. <b>2011</b> , 117, e198-206	126
1516	Mammalian NADH:ubiquinone oxidoreductase (Complex I) and nicotinamide nucleotide transhydrogenase (Nnt) together regulate the mitochondrial production of H <sub>2</sub> O <sub>2</sub> implications for their role in disease, especially cancer. <b>2011</b> , 43, 541-64	24
1515	The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. <b>2011</b> , 30, 199-210	57
1514	Chromosomes and cancer cells. <b>2011</b> , 19, 433-44	95

1513	Inhibitors of succinate: quinone reductase/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death. <b>2011</b> , 28, 2695-730	93
1512	Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. <b>2011</b> , 102, 477-84	63
1511	The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. <b>2011</b> , 102, 353-66	28
1510	PI3Kinase signaling in glioblastoma. <b>2011</b> , 103, 417-27	56
1509	Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. <b>2011</b> , 104, 339-49	37
1508	Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. <b>2011</b> , 105, 181-90	13
1507	IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. <b>2011</b> , 105, 345-57	81
1506	IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. <b>2011</b> , 105, 591-600	55
1505	Somatic variation and cancer: therapies lost in the mix. <b>2011</b> , 130, 79-91	34
1504	IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. <b>2011</b> , 27, 87-94	126
1503	Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. <b>2011</b> , 121, 753-61	40
1502	High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. <b>2011</b> , 122, 367-9	14
1501	High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. <b>2011</b> , 28, 107-14	19
1500	Loss of heterozygosity analysis in malignant gliomas. <b>2011</b> , 28, 191-6	18
1499	Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). <b>2011</b> , 28, 185-90	21
1498	New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. <b>2011</b> , 28, 203-8	6
1497	Chemotherapie bei Gliomen. <b>2011</b> , 17, 44-54	1
1496	[Tyrosine kinase inhibitors in oncology]. <b>2011</b> , 52, 595-600	2

1495	Inborn and acquired metabolic defects in cancer. <b>2011</b> , 89, 213-20	113
1494	Therapeutic targeting of cancer cell metabolism. <b>2011</b> , 89, 205-12	133
1493	Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. <b>2011</b> , 89, 1423-33	60
1492	MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme. <b>2011</b> , 44, 235-49	39
1491	New DNA sequencing technologies open a promising era for cancer research and treatment. <b>2011</b> , 13, 301-6	14
1490	Can metabolic plasticity be a cause for cancer? Warburg-Waddington legacy revisited. <b>2011</b> , 2, 113-22	9
1489	Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. <b>2011</b> , 32, 325-33	22
1488	Genomic profiles of glioma. <b>2011</b> , 11, 291-7	34
1487	Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment. <b>2011</b> , 13, 26-36	1
1486	Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. <b>2011</b> , 10, 17	44
1485	The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation. <b>2011</b> , 10, 83	40
1484	Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. <b>2011</b> , 9, 16	36
1483	Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. <b>2011</b> , 6, 115	79
1482	Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. <b>2011</b> , 4, 68	146
1481	Clinical cancer genomics: how soon is now?. <b>2011</b> , 223, 318-26	30
1480	Lessons from the deep study of rare tumours. <b>2011</b> , 224, 306-8	5
1479	Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. <b>2011</b> , 56, 379-83	27
1478	Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. <b>2011</b> , 11, 4139-54	11

1477	Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. <b>2011</b> , 29, 20-31	67
1476	Combination of a p16 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. <b>2011</b> , 29, 590-9	33
1475	Functional genomics of the brain: uncovering networks in the CNS using a systems approach. <b>2011</b> , 3, 628-48	10
1474	Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. <b>2011</b> , 104, 679-84	10
1473	IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. <b>2011</b> , 69, 455-63	114
1472	Current concepts and management of glioblastoma. <b>2011</b> , 70, 9-21	319
1471	Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. <b>2011</b> , 59, 1200-4	36
1470	Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. <b>2011</b> , 59, 1205-12	26
1469	The origins of glioma: E Pluribus Unum?. <b>2011</b> , 59, 1135-47	65
1468	Drosophila melanogaster as a model system for human brain cancers. <b>2011</b> , 59, 1364-76	34
1467	Molecular subclassification of diffuse gliomas: seeing order in the chaos. <b>2011</b> , 59, 1190-9	180
1466	Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma. <b>2011</b> , 33, 1233-40	2
1465	LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas. <b>2011</b> , 50, 1010-20	14
1464	Benefits of interferon- $\beta$ and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. <b>2011</b> , 117, 1721-30	72
1463	Cancer genome variation in children, adolescents, and young adults. <b>2011</b> , 117, 2262-7	4
1462	Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. <b>2011</b> , 32, E2148-75	32
1461	Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. <b>2011</b> , 32, 1028-35	9
1460	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. <b>2011</b> , 128, 1095-103	64

1459	Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. <b>2011</b> , 128, 1981-8	41
1458	Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. <b>2011</b> , 44, 779-83	15
1457	Molecular markers in low-grade gliomas: predictive or prognostic?. <b>2011</b> , 17, 4588-99	145
1456	Genomic and epigenomic integration identifies a prognostic signature in colon cancer. <b>2011</b> , 17, 1535-45	125
1455	Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. <b>2011</b> , 114, 587-94	133
1454	Antitumor effect of aspirin in glioblastoma cells by modulation of $\beta$ catenin/T-cell factor-mediated transcriptional activity. <b>2011</b> , 115, 780-8	18
1453	Genomic alterations and the pathogenesis of glioblastoma. <b>2011</b> , 10, 1174-5	3
1452	Discovering neurosurgery: new frontiers. <b>2011</b> , 115, 1053-66	0
1451	Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. <b>2011</b> , 19, 1793-801	38
1450	Brain tumor pathway identification by integrating transcriptome and interactome data. <b>2011</b> ,	
1449	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. <b>2011</b> , 29, 4482-90	337
1448	Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. <b>2011</b> , 13, 700-9	25
1447	Challenging issues in pediatric oncology. <b>2011</b> , 8, 540-9	149
1446	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. <b>2011</b> , 103, 143-53	194
1445	New phosphatidylinositol 3-kinase inhibitors for cancer. <b>2011</b> , 20, 507-18	48
1444	RAS Interaction with PI3K: More Than Just Another Effector Pathway. <b>2011</b> , 2, 261-74	463
1443	Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. <b>2011</b> , 8, 135-48	82
1442	Epigenetic regulation of gene expression in physiological and pathological brain processes. <b>2011</b> , 91, 603-49	279



1441	Efficient simulation under a population genetics model of carcinogenesis. <b>2011</b> , 27, 837-43	9
1440	Molecular profile of oligodendrogliomas in young patients. <b>2011</b> , 13, 1099-106	37
1439	Silencing IL-13R $\alpha$ promotes glioblastoma cell death via endogenous signaling. <b>2011</b> , 10, 1149-60	44
1438	Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. <b>2011</b> , 20, 225-32	38
1437	Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. <b>2011</b> , 71, 6061-72	274
1436	Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. <b>2011</b> , 208, 313-26	527
1435	A 4-gene signature associated with clinical outcome in high-grade gliomas. <b>2011</b> , 17, 317-27	55
1434	Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. <b>2011</b> , 64, 835-44	38
1433	NFKBIA deletion in glioblastomas. <b>2011</b> , 364, 627-37	188
1432	A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. <b>2011</b> , 17, 3686-96	63
1431	Targeted therapy for BRAFV600E malignant astrocytoma. <b>2011</b> , 17, 7595-604	128
1430	Understanding the enemy. <b>2011</b> , 3, 98ps37	4
1429	Low-grade gliomas in adults. <b>2011</b> , 1-18	14
1428	Making sense of cancer genomic data. <b>2011</b> , 25, 534-55	260
1427	Five-dimensional teleparallel theory equivalent to general relativity, the axially symmetric solution, energy and spatial momentum. <b>2011</b> , 20, 110402	
1426	A 2D nonlinear inversion of well-seismic data. <b>2011</b> , 27, 055005	5
1425	Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. <b>2011</b> , 103, 598-606	42
1424	Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. <b>2011</b> , 108, 12384-9	33

1423	The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. <b>2011</b> , 13, 736-47	76
1422	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. <b>2011</b> , 108, 3270-5	34 <sup>o</sup>
1421	Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. <b>2011</b> , 13, 42-50	33
1420	Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. <b>2011</b> , 13, 1178-91	64
1419	Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer. <b>2011</b> , 3, 1141-57	21
1418	IDH1 and IDH2 mutations in pediatric acute leukemia. <b>2011</b> , 25, 1570-7	62
1417	Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. <b>2011</b> , 13, 610-21	29
1416	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. <b>2011</b> , 5, 265-314	27
1415	Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. <b>2011</b> , 59, 489-503	28
1414	Genetics of glioblastoma: a window into its imaging and histopathologic variability. <b>2011</b> , 31, 1717-40	36
1413	Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. <b>2011</b> , 71, 3471-81	9
1412	Molecular cytogenetic analysis of a gliosarcoma with osseous metaplasia. <b>2011</b> , 134, 88-95	3
1411	Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery. <b>2011</b> , 28, 771-92	24
1410	Neurooncology. <b>2011</b> , 39, 124-8	1
1409	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. <b>2011</b> , 13, 84-98	99
1408	A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. <b>2011</b> , 13, 290-7	91
1407	Advancing a clinically relevant perspective of the clonal nature of cancer. <b>2011</b> , 108, 12054-9	89
1406	The novel chemical entity YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppressing repair of DNA double-strand breaks and enhancing radiosensitization. <b>2011</b> , 17, 6490-9	21

1405	Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. <b>2011</b> , 71, 4550-61	122
1404	PIK3R1 (p85) is somatically mutated at high frequency in primary endometrial cancer. <b>2011</b> , 71, 4061-7	166
1403	Platelet-derived growth factor receptor alpha in glioma: a bad seed. <b>2011</b> , 30, 590-602	30
1402	RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. <b>2011</b> , 13, 1277-87	9
1401	Stem cells in brain tumor development. <b>2011</b> , 94, 15-44	13
1400	A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. <b>2011</b> , 208, 689-702	65
1399	Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. <b>2011</b> , 71, 4106-16	54
1398	Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. <b>2011</b> , 15, 829-46	42
1397	WITHDRAWN: Cytogenetic and molecular genetic study on glioblastoma arising in granular cell astrocytoma: a case report. <b>2011</b> ,	1
1396	Targeting ErbB receptors in high-grade glioma. <b>2011</b> , 17, 2468-87	27
1395	Targeting the AKT pathway in glioblastoma. <b>2011</b> , 17, 2411-20	60
1394	The role of Hepatitis C Virus in the dynamic protein interaction networks of hepatocellular cirrhosis and carcinoma. <b>2011</b> , 4, 5-18	12
1393	Mislocalization of the E3 ligase, Etransducin repeat-containing protein 1 (ETrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. <b>2011</b> , 286, 19777-88	36
1392	Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. <b>2011</b> , 29, 3999-4006	228
1391	Epithelial phosphatidylinositol-3-kinase signaling is required for Ecatenin activation and host defense against Citrobacter rodentium infection. <b>2011</b> , 79, 1863-72	36
1390	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. <b>2011</b> , 39, D945-50	1774
1389	MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. <b>2011</b> , 71, 2392-402	105
1388	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <b>2011</b> , 7, 818-26	208

1387	Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. <b>2011</b> , 105, 1235-43	19
1386	Advances in malignant glioma drug discovery. <b>2011</b> , 6, 739-53	15
1385	Novel ways to target brain tumour metabolism. <b>2011</b> , 15, 1227-39	12
1384	K <sup>+</sup> channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. <i>Science</i> , <b>2011</b> , 331, 768-72	33-3 707
1383	Predicting the functional impact of protein mutations: application to cancer genomics. <b>2011</b> , 39, e118	1237
1382	Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. <b>2011</b> , 135, 35-45	126
1381	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. <b>2011</b> , 22, 2616-2624	279
1380	DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. <b>2011</b> , 7, 1335-46	32
1379	A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. <b>2011</b> , 108, 1591-6	94
1378	Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. <b>2011</b> , 71, 7280-90	78
1377	How genetically engineered mouse tumor models provide insights into human cancers. <b>2011</b> , 29, 2273-81	97
1376	Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. <b>2011</b> , 2011, bar018	41
1375	Genetic alterations in glioma. <b>2011</b> , 3, 1129-40	19
1374	Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma. <b>2011</b> , 259, 540-9	32
1373	Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. <b>2011</b> , 7, e1001099	100
1372	Elevated citrate in pediatric astrocytomas with malignant progression. <b>2011</b> , 13, 1107-17	26
1371	Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. <b>2011</b> , 13, 317-23	233
1370	International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data. <b>2011</b> , 2011, bar026	382

1369	Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?. <b>2011</b> , 13, 1262-4	6
1368	The UCSC Cancer Genomics Browser: update 2011. <b>2011</b> , 39, D951-9	49
1367	Role of isocitrate dehydrogenase in glioma. <b>2011</b> , 11, 1399-409	12
1366	Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma. <b>2011</b> , 80, 1076-84	23
1365	Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. <b>2011</b> , 7, e1002245	55
1364	Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. <b>2011</b> , 7, e1002110	6
1363	Accurate reconstruction of the temporal order of mutations in neoplastic progression. <b>2011</b> , 4, 1135-44	44
1362	Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. <b>2012</b> , 14, 160-74	20
1361	Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. <b>2012</b> , 86, 854-64	113
1360	Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma. <b>2012</b> , 8, e1002488	110
1359	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. <b>2012</b> , 26, 101-5	112
1358	Evolution of the voltage sensor domain of the voltage-sensitive phosphoinositide phosphatase VSP/TPTE suggests a role as a proton channel in eutherian mammals. <b>2012</b> , 29, 2147-55	16
1357	A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. <b>2012</b> , 31, 1364-78	243
1356	p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. <b>2012</b> , 14, 870-81	120
1355	The cancer antigenome. <b>2013</b> , 32, 194-203	172
1354	Oncogenic extracellular vesicles in brain tumor progression. <b>2012</b> , 3, 294	86
1353	Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation. <b>2012</b> , 10, e1001320	105
1352	Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. <b>2012</b> , 13, 1951-2011	106

1351	The genomic landscape of prostate cancer. <b>2012</b> , 3, 69	36
1350	Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. <b>2012</b> , 14, 426-39	44
1349	Molecular biology of brain tumors. <b>2012</b> , 104, 23-34	10
1348	CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. <b>2012</b> , 14, 1254-64	37
1347	TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. <b>2012</b> , 2012, 161837	112
1346	Interactions between epigenetics and metabolism in cancers. <b>2012</b> , 2, 163	59
1345	Clear cell tumors of the central nervous system: a case-based review. <b>2012</b> , 136, 915-26	3
1344	Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A. <b>2012</b> , 23, 1243-53	27
1343	Key concepts in glioblastoma therapy. <b>2012</b> , 83, 753-60	59
1342	Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. <b>2012</b> , 23, 533-42	80
1341	c-Myc and cancer metabolism. <b>2012</b> , 18, 5546-53	466
1340	Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. <b>2012</b> , 109, E2998-3007	52
1339	Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. <b>2012</b> , 18, 69-81	136
1338	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. <b>2012</b> , 83, 20	6
1337	Novel delivery strategies for glioblastoma. <b>2012</b> , 18, 89-99	91
1336	Molecular predictors of outcome in low-grade glioma. <b>2012</b> , 25, 767-73	41
1335	Individualized targeted therapy for glioblastoma: fact or fiction?. <b>2012</b> , 18, 40-4	57
1334	Oligodendrogliomas: new insights from the genetics and perspectives. <b>2012</b> , 24, 687-93	21

1333	Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions. <b>2012</b> , 21, 214-20	16
1332	Gliosis versus glioma?: don't grade until you know. <b>2012</b> , 19, 239-49	34
1331	The molecular basis for novel therapies. <b>2012</b> , 18, 32-9	3
1330	Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. <b>2012</b> , 40, D978-83	31
1329	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. <b>2012</b> , 22, 2339-55	137
1328	Cancer-associated isocitrate dehydrogenase mutations. <b>2012</b> , 17, 5-8	12
1327	Integrative functional genomics identifies RINT1 as a novel GBM oncogene. <b>2012</b> , 14, 1325-31	12
1326	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. <b>2012</b> , 21, 5397-405	111
1325	Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). <b>2012</b> , 287, 42180-94	68
1324	Genomic analysis and selected molecular pathways in rare cancers. <b>2012</b> , 9, 065004	7
1323	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. <b>2012</b> , 4, 116ra5	134
1322	Efficient sampling for Bayesian inference of conjunctive Bayesian networks. <b>2012</b> , 28, 2318-24	16
1321	The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. <b>2012</b> , 72, 5878-88	113
1320	Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. <b>2012</b> , 11, M111.014688	70
1319	Therapeutic Kinase Inhibitors. <b>2012</b> ,	1
1318	Retina restored and brain abnormalities ameliorated by single-copy knock-in of human NR2E1 in null mice. <b>2012</b> , 32, 1296-311	10
1317	Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. <b>2012</b> , 92, 151-62	102
1316	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. <b>2012</b> , 14, 1465-72	33

1315	Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. <b>2012</b> , 6, 356-64	22
1314	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. <b>2012</b> , 5, 881-94	58
1313	Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. <b>2012</b> , 97, E1995-2005	101
1312	Addressing diffuse glioma as a systemic brain disease with single-cell analysis. <b>2012</b> , 69, 523-6	93
1311	Expanding the reach of cancer metabolomics. <b>2012</b> , 5, 1337-40	16
1310	Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. <b>2012</b> , 1, 137-48	5
1309	Blood cell fate changes without cell cycle transition. <b>2012</b> , 11, 3154-5	1
1308	Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. <b>2012</b> , 12, 197-209	159
1307	The yin and yang of proliferation and differentiation: cyclin D1 inhibits differentiation factors ChREBP and HNF4B. <b>2012</b> , 11, 3156-7	6
1306	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. <b>2012</b> , 109, 14476-81	208
1305	PDGF and PDGF receptors in glioma. <b>2012</b> , 117, 99-112	120
1304	Ubiquitin and the DNA damage response: a new handle on histones. <b>2012</b> , 11, 3153	3
1303	Fenofibrate triggers apoptosis of glioblastoma cells in vitro: new insights for therapy. <b>2012</b> , 11, 3154	5
1302	Tetraploid cancer cell precursors in ovarian carcinoma. <b>2012</b> , 11, 3157-8	5
1301	A roundabout way to cancer. <b>2012</b> , 114, 187-235	75
1300	Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. <b>2012</b> , 16, 113-22	20
1299	An in vivo patient-derived model of endogenous IDH1-mutant glioma. <b>2012</b> , 14, 184-91	130
1298	An efficient overlap graph coarsening approach for modeling short reads. <b>2012</b> ,	1



1297	Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. <b>2012</b> , 106, 1816-25	7
1296	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. <b>2012</b> , 26, 475-80	129
1295	Advances in Cancer Stem Cell Biology. <b>2012</b> ,	2
1294	Spectrum of somatic mitochondrial mutations in five cancers. <b>2012</b> , 109, 14087-91	162
1293	Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells. <b>2012</b> , 72, 3381-92	12
1292	Magnetic resonance metabolic imaging of glioma. <b>2012</b> , 4, 116ps1	5
1291	A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas. <b>2012</b> , 10, 925-36	37
1290	Decision making and management of gliomas: practical considerations. <b>2012</b> , 23 Suppl 10, x33-40	9
1289	Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. <b>2012</b> , 2, 676-8	1
1288	Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. <b>2012</b> , 109, 4251-6	64
1287	cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a. <b>2012</b> , 109, 15805-10	97
1286	Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. <b>2012</b> , 10, 208-17	32
1285	Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. <b>2012</b> , 22, 208-19	95
1284	Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. <b>2012</b> , 14, 518-25	53
1283	Ink4a/Arf loss promotes tumor recurrence following Ras inhibition. <b>2012</b> , 14, 34-42	8
1282	PI3Ks-drug targets in inflammation and cancer. <b>2012</b> , 58, 111-81	7
1281	Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. <b>2012</b> , 61, 1085-94	110
1280	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. <b>2012</b> , 17, 72-9	532

1279	Moving toward molecular classification of diffuse gliomas in adults. <b>2012</b> , 79, 1917-26	54
1278	Functional impact bias reveals cancer drivers. <b>2012</b> , 40, e169	238
1277	On the origin of glioma. <b>2012</b> , 117, 113-21	51
1276	Promoter Methylation Analysis of IDH Genes in Human Gliomas. <b>2012</b> , 2, 193	5
1275	Stress-sensitive neurosignalling in depression: an integrated network biology approach to candidate gene selection for genetic association analysis. <b>2012</b> , 4, e21	2
1274	Myeloid neoplasias: what molecular analyses are telling us. <b>2012</b> , 2012, 321246	2
1273	Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach. <b>2012</b> , 8, 598-601	25
1272	Current trends in targeted therapies for glioblastoma multiforme. <b>2012</b> , 2012, 878425	102
1271	IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?. <b>2012</b> , 31, 278-82	18
1270	Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events. <b>2012</b> , 2012, 519807	11
1269	The emerging role of fumarate as an oncometabolite. <b>2012</b> , 2, 85	108
1268	Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. <b>2012</b> , 2, 186	67
1267	DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology. <b>2012</b> , 2012, 956958	16
1266	miR-34 - a microRNA replacement therapy is headed to the clinic. <b>2012</b> , 3, 120	522
1265	Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. <b>2012</b> , 287, 14012-22	17
1264	Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. <b>2012</b> , 13, 305-16	42
1263	An analysis of substitution, deletion and insertion mutations in cancer genes. <b>2012</b> , 40, 6401-13	32
1262	Genetics of adrenocortical disease: an update. <b>2012</b> , 19, 159-67	6

1261	Studying a complex tumor: potential and pitfalls. <b>2012</b> , 18, 107-14	23
1260	Inhibition and termination of physiological responses by GTPase activating proteins. <b>2012</b> , 92, 237-72	41
1259	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. <b>2012</b> , 4, 116ra4	297
1258	KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. <b>2012</b> , 135, 1027-41	37
1257	IDH1 mutation of gliomas with long-term survival analysis. <b>2012</b> , 28, 1639-44	32
1256	Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma. <b>2012</b> , 4, 1321-1324	17
1255	Mitocans, Mitochondria-Targeting Anticancer Drugs. <b>2012</b> , 55-91	1
1254	Thérapies moléculaires ciblées et antiangiogéniques dans le traitement des glioblastomes. <b>2012</b> , 9, 1-13	
1253	Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review). <b>2012</b> , 3, 7-10	2
1252	Identification of disease-relevant genes for molecularly-targeted drug discovery. <b>2012</b> , 12, 1-13	9
1251	The VM Mouse Model of Glioblastoma Multiforme. <b>2012</b> , 39-55	4
1250	Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases. <b>2012</b> , 36, 620-8	28
1249	Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. <b>2012</b> , 24, 83-9	42
1248	Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data. <b>2012</b> , 33, 940-3	47
1247	Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme. <b>2012</b> , 10,	0
1246	Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. <b>2012</b> , 2, 273	42
1245	Identification of prognostic biomarkers for glioblastomas using protein expression profiling. <b>2012</b> , 40, 1122-32	17
1244	Targeting PI3 kinase/AKT/mTOR signaling in cancer. <b>2012</b> , 17, 69-95	176

1243	Molecular genetics of acute myeloid leukemia. 204-238	1
1242	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. <b>2012</b> , 119, 1901-3	364
1241	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. <b>2012</b> , 40, 2058-62	19
1240	Glioma and Other Neuroepithelial Neoplasms. <b>2012</b> , 767-794	
1239	Primary brain tumours in adults. <b>2012</b> , 379, 1984-96	447
1238	How cancer metabolism is tuned for proliferation and vulnerable to disruption. <b>2012</b> , 491, 364-73	652
1237	Medulloblastomics: the end of the beginning. <b>2012</b> , 12, 818-34	443
1236	A novel missense-mutation-related feature extraction scheme for 'driver' mutation identification. <b>2012</b> , 28, 2948-55	36
1235	IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension. <b>2012</b> , 22, 619-24	15
1234	Global profiling strategies for mapping dysregulated metabolic pathways in cancer. <b>2012</b> , 16, 565-77	91
1233	Genetically-defined metabolic reprogramming in cancer. <b>2012</b> , 23, 552-9	60
1232	Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. <b>2012</b> , 124, 883-91	48
1231	Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. <b>2012</b> , 104, 1458-69	45
1230	ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. <b>2012</b> , 341, 859-72	36
1229	Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. <b>2012</b> , 18, 1835-40	521
1228	Lull1 parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells. <b>2012</b> , 86, 7280-91	18
1227	microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF- $\beta$ signaling in glioblastoma. <b>2012</b> , 2, 736-49	90
1226	Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. <b>2012</b> , 103, 1871-9	32

1225	Cancer genomics and pathology: all together now. <b>2012</b> , 62, 647-59	5
1224	Prospective, high-throughput molecular profiling of human gliomas. <b>2012</b> , 110, 89-98	44
1223	Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. <b>2012</b> , 21, 1391-415	50
1222	Glioblastoma multiforme: overview of current treatment and future perspectives. <b>2012</b> , 26, 825-53	105
1221	Emerging real-time technologies in molecular medicine and the evolution of integrated 'pharmacomics' approaches to personalized medicine and drug discovery. <b>2012</b> , 136, 295-304	11
1220	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. <b>2012</b> , 124, 615-25	295
1219	Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. <b>2012</b> , 18, 5188-95	49
1218	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. <b>2012</b> , 26, 2038-49	218
1217	SPRED proteins provide a NF-ty link to Ras suppression. <b>2012</b> , 26, 1515-9	9
1216	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. <b>2012</b> , 2, 458-71	240
1215	Delving into somatic variation in sporadic melanoma. <b>2012</b> , 25, 155-70	33
1214	IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. <b>2012</b> , 18, 5562-71	254
1213	Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. <b>2012</b> , 181, 675-83	83
1212	Stem Cells and Cancer Stem Cells: New Insights. <b>2012</b> , 17-31	
1211	An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. <b>2012</b> , 118, 232-40	33
1210	Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. <b>2012</b> , 30, 2161-72	8
1209	IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. <b>2012</b> , 32, 30-7	17
1208	Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy. <b>2012</b> , 65, 399-435	8

1207	Issues in Omics Data Integration for Gene Set Analysis and Aberrant Pathway Identification. <b>2012</b> , 73, 528-534	
1206	Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. <b>2012</b> , 90, 1161-1171	70
1205	Malignant transformation in pediatric spinal intramedullary tumors: case-based update. <b>2012</b> , 28, 1679-86	17
1204	Papillary glioneuronal tumor--a rare entity: report of four cases and brief review of literature. <b>2012</b> , 28, 1897-904	21
1203	Molecular markers of glioma: an update on recent progress and perspectives. <b>2012</b> , 138, 1971-81	43
1202	IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. <b>2012</b> , 17, 551-61	39
1201	IDH1 mutations inhibit multiple $\alpha$ -ketoglutarate-dependent dioxygenase activities in astrogloma. <b>2012</b> , 109, 253-60	25
1200	Analysis of NADP <sup>+</sup> -dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. <b>2012</b> , 109, 477-84	11
1199	Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. <b>2012</b> , 110, 205-13	26
1198	Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. <b>2012</b> , 110, 227-35	14
1197	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. <b>2012</b> , 110, 279-85	26
1196	Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. <b>2012</b> , 110, 195-203	49
1195	The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. <b>2012</b> , 110, 325-33	60
1194	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. <b>2012</b> , 22, 425-37	1243
1193	Methylome alterations "mark" new therapeutic opportunities in glioblastoma. <b>2012</b> , 22, 417-8	8
1192	ENTPD5-mediated modulation of ATP results in altered metabolism and decreased survival in glioblastoma multiforme. <b>2012</b> , 33, 2411-21	13
1191	KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. <b>2012</b> , 181, 1007-16	23
1190	Characterising Somatic Mutations in Cancer Genome by Means of Next-generation Sequencing. <b>2012</b> ,	

1189	Detection of IDH1 mutation in the plasma of patients with glioma. <b>2012</b> , 79, 1693-8	63
1188	Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. <b>2012</b> , 12, 1-14	
1187	Something old and something new about molecular diagnostics in gliomas. <b>2012</b> , 5, 919-939	11
1186	IDH mutations in human glioma. <b>2012</b> , 23, 471-80	42
1185	Stem cells in gliomas. <b>2012</b> , 104, 63-73	9
1184	Key contribution of CPEB4-mediated translational control to cancer progression. <b>2011</b> , 18, 83-90	113
1183	Fluorescent phosphatidylinositol 4,5-bisphosphate derivatives with modified 6-hydroxy group as novel substrates for phospholipase C. <b>2012</b> , 51, 5300-6	8
1182	Clinical and molecular characteristics of congenital glioblastoma. <b>2012</b> , 14, 931-41	35
1181	Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. <b>2012</b> , 44, 251-3	1081
1180	Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: marker or maker of the diabetic phenotype?. <b>2012</b> , 118, 156-89	37
1179	Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. <b>2012</b> , 19 Suppl 3, S608-19	24
1178	A new branch on the tree: next-generation sequencing in the study of cancer evolution. <b>2012</b> , 23, 237-42	27
1177	Alterations of metabolic genes and metabolites in cancer. <b>2012</b> , 23, 370-80	84
1176	New aspects of the Warburg effect in cancer cell biology. <b>2012</b> , 23, 352-61	228
1175	Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. <b>2012</b> , 39, 23-34	27
1174	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. <b>2012</b> , 18, 2490-501	108
1173	Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?. <b>2012</b> , 11, 3143-4	13
1172	Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. <b>2012</b> , 10, 293-304	50

1171	Cancer biomarkers: selecting the right drug for the right patient. <b>2012</b> , 11, 201-14	202
1170	Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. <b>2012</b> , 109, 14586-91	76
1169	What are we learning from the cancer genome?. <b>2012</b> , 9, 621-30	43
1168	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. <b>2012</b> , 3, 850-5	155
1167	Cancer cell metabolism: one hallmark, many faces. <b>2012</b> , 2, 881-98	609
1166	Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. <b>2012</b> , 12, 635-42	88
1165	Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. <b>2012</b> , 16, 161-70	20
1164	Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. <b>2012</b> , 75, 3898-913	33
1163	IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells. <b>2012</b> , 423, 553-6	19
1162	Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1 $\alpha$ and Eatenin signaling: possible impact on glioma cell metastasis and chemo-resistance. <b>2012</b> , 44, 770-5	44
1161	Genetically engineered mouse models of diffuse gliomas. <b>2012</b> , 88, 72-9	18
1160	Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. <b>2012</b> , 148, 259-72	483
1159	Cellular metabolism and disease: what do metabolic outliers teach us?. <b>2012</b> , 148, 1132-44	509
1158	Opening Pandora's Box--the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. <b>2012</b> , 22, 3-9	31
1157	Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. <b>2012</b> , 11, 133-44	56
1156	Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles. <b>2012</b> , 114, 1207-10	12
1155	Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. <b>2012</b> , 23, 362-9	269
1154	Temozolomide and other potential agents for the treatment of glioblastoma multiforme. <b>2012</b> , 23, 307-22, ix	59



1153	Methods for visual mining of genomic and proteomic data atlases. <b>2012</b> , 13, 58	7
1152	Genetic oxidative stress variants and glioma risk in a Chinese population: a hospital-based case-control study. <b>2012</b> , 12, 617	19
1151	Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids. <b>2012</b> , 12, 14	12
1150	Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. <b>2012</b> , 11, 20	27
1149	Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors. <b>2012</b> , 7, 66	7
1148	Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks. <b>2012</b> , 6, 29	58
1147	Cancer core modules identification through genomic and transcriptomic changes correlation detection at network level. <b>2012</b> , 6, 64	2
1146	Metastasis. <b>2012</b> , 215-252	
1145	Genetics of adult glioma. <b>2012</b> , 205, 613-21	566
1144	Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. <b>2012</b> , 1826, 370-84	142
1143	Magnetic resonance spectroscopy of cancer metabolism and response to therapy. <b>2012</b> , 177, 398-435	10
1142	Enzyme redesign guided by cancer-derived IDH1 mutations. <b>2012</b> , 8, 887-9	14
1141	The future of glioma treatment: stem cells, nanotechnology and personalized medicine. <b>2012</b> , 8, 1149-56	15
1140	Epigenetic Alterations in Glioblastoma Multiforme. <b>2012</b> , 71-90	1
1139	Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. <b>2012</b> , 31, 1533-45	43
1138	Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. <b>2012</b> , 25, 732-9	69
1137	Multiple roles for the p85 $\beta$ isoform in the regulation and function of PI3K signalling and receptor trafficking. <b>2012</b> , 441, 23-37	70
1136	Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). <b>2012</b> , 3, 9-14	60

1135	The Pediatric Cancer Genome Project. <b>2012</b> , 44, 619-22	239
1134	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <b>2012</b> , 482, 226-31	1655
1133	Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. <b>2012</b> , 7, e30339	99
1132	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. <b>2012</b> , 488, 656-9	395
1131	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. <b>2012</b> , 18, 624-9	584
1130	Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. <b>2012</b> , 31, 2491-8	153
1129	Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. <b>2012</b> , 7, e32764	38
1128	Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. <b>2012</b> , 7, e43403	74
1127	Genes, Respiration, Viruses, and Cancer. <b>2012</b> , 145-176	1
1126	Overview of primary brain tumors: pathologic classification, epidemiology, molecular biology, and prognostic markers. <b>2012</b> , 26, 715-32	22
1125	Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. <b>2012</b> , 4, 142ra94	204
1124	Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. <b>2012</b> , 44, 1117-21	313
1123	A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. <b>2012</b> , 1826, 423-33	59
1122	A novel treatment for glioblastoma: integrin inhibition. <b>2012</b> , 12, 421-35	31
1121	Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. <b>2012</b> , 43, 1552-8	175
1120	IDH mutations in acute myeloid leukemia. <b>2012</b> , 43, 1541-51	92
1119	Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. <b>2012</b> , 16, 255-9	16
1118	Molecular tools for companion diagnostics. <b>2012</b> , 29, 634-40	17

1117	TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. <b>2012</b> , 7, e31605	66
1116	Biomarker Discovery in Central Nervous System Neoplasms: Past, Present and Future. <b>2012</b> , 107-119	
1115	In vivo models of primary brain tumors: pitfalls and perspectives. <b>2012</b> , 14, 979-93	169
1114	The disturbed blood-brain barrier in human glioblastoma. <b>2012</b> , 33, 579-89	178
1113	Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. <b>2012</b> , 33, 1349-55	207
1112	IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. <b>2012</b> , 138, 177-84	26
1111	Cancer metabolism: current perspectives and future directions. <b>2012</b> , 3, e248	282
1110	Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy. <b>2012</b> , 20, 264-71	15
1109	Is there a biological cost of protein disorder? Analysis of cancer-associated mutations. <b>2012</b> , 8, 296-307	40
1108	Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. <b>2012</b> , 7, e44372	35
1107	Biomarkers classification and therapeutic decision-making for malignant gliomas. <b>2012</b> , 13, 417-36	22
1106	RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. <b>2012</b> , 14, 526-34	17
1105	Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. <b>2012</b> , 11, 268-74	5
1104	A model of early human embryonic stem cell differentiation reveals inter- and intracellular changes on transition to squamous epithelium. <b>2012</b> , 21, 1250-63	16
1103	Development of Antibody-Based Therapeutics. <b>2012</b> ,	5
1102	Neurofibromatosis Type 1. <b>2012</b> ,	16
1101	Autocrine control of glioma cells adhesion and migration through IRE1 $\beta$ -mediated cleavage of SPARC mRNA. <b>2012</b> , 125, 4278-87	78
1100	DNA replication timing and selection shape the landscape of nucleotide variation in cancer genomes. <b>2012</b> , 3, 1004	91

1099	Stem Cells and Cancer Stem Cells, Volume 1. <b>2012,</b>	2
1098	Tumors of the Central Nervous System, Volume 5. <b>2012,</b>	
1097	Phosphoinositides I: Enzymes of Synthesis and Degradation. <b>2012,</b>	6
1096	Proteomic analysis reveals drug accessible cell surface N-glycoproteins of primary and established glioblastoma cell lines. <b>2012,</b> 11, 4885-93	19
1095	Regulation of Parkin E3 ubiquitin ligase activity. <b>2012,</b> 69, 3053-67	52
1094	Glioma. <b>2012,</b>	2
1093	Improving accuracy for cancer classification with a new algorithm for genes selection. <b>2012,</b> 13, 298	39
1092	Pediatric Cancer, Volume 2. <b>2012,</b>	0
1091	Clinical trials of small molecule inhibitors in high-grade glioma. <b>2012,</b> 23, 407-16	9
1090	Glioblastoma and malignant astrocytoma. <b>2012,</b> 384-407	1
1089	DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. <b>2012,</b> 13, R124	156
1088	Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. <b>2012,</b> 4, 89	73
1087	Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival. <b>2012,</b> 4, 76	39
1086	Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types. <b>2012,</b> 4, 28	34
1085	Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. <b>2012,</b> 7, e33393	128
1084	GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors. <b>2012,</b> 7, e35943	13
1083	Genome-wide gene amplification during differentiation of neural progenitor cells in vitro. <b>2012,</b> 7, e37422	14
1082	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. <b>2012,</b> 7, e41036	128

1081	Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. <b>2012</b> , 7, e41298	38
1080	Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. <b>2012</b> , 7, e43468	40
1079	Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels. <b>2012</b> , 7, e46088	28
1078	Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. <b>2012</b> , 7, e39242	198
1077	Histopathology of brain tumors. <b>2012</b> , 138-187	
1076	Harnessing Information Using Genomic Platforms. <b>2012</b> , 727-744	
1075	Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. <b>2012</b> , 50, 301-21	66
1074	PIK3R1 (phosphoinositide-3-kinase, regulatory subunit 1 (alpha)). <b>2012</b> ,	
1073	Neurogenetics and the molecular biology of human brain tumors. <b>2012</b> , 83-101	
1072	Glioblastoma: biology, genetics, and behavior. <b>2012</b> , 102-7	8
1071	Molecular biomarkers of glioblastoma: current targets and clinical implications. <b>2012</b> , 63	4
1070	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. <b>2012</b> , 3, 709-22	439
1069	MAPK pathway activation in pilocytic astrocytoma. <b>2012</b> , 69, 1799-811	152
1068	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. <b>2012</b> , 366, 883-892	5559
1067	Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. <b>2012</b> , 2, 328-43	145
1066	Links between metabolism and cancer. <b>2012</b> , 26, 877-90	707
1065	Cancer genomics: technology, discovery, and translation. <b>2012</b> , 30, 647-60	134
1064	Molecular pathogenesis of IDH mutations in gliomas. <b>2012</b> , 29, 131-9	91

1063	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. <b>2012</b> , 483, 479-83	1373
1062	Malignant glioma: lessons from genomics, mouse models, and stem cells. <b>2012</b> , 149, 36-47	416
1061	Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. <b>2012</b> , 72, 1614-20	90
1060	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <b>2012</b> , 483, 474-8	1393
1059	Clinically useful biomarkers in neurooncology. <b>2012</b> , 5, 201-204	1
1058	The MET oncogene is a functional marker of a glioblastoma stem cell subtype. <b>2012</b> , 72, 4537-50	104
1057	Molecular biology of glioma. <b>2012</b> , 746, 2-11	50
1056	Emerging insights into the molecular and cellular basis of glioblastoma. <b>2012</b> , 26, 756-84	388
1055	Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. <b>2012</b> , 5, 5	59
1054	The influence of race and ethnicity on the biology of cancer. <b>2012</b> , 12, 648-53	37
1053	Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma. <b>2012</b> , 51, 675-88	12
1052	The renal v-ATPase a4 subunit is expressed in specific subtypes of human gliomas. <b>2012</b> , 60, 1004-12	18
1051	Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas. <b>2012</b> , 131, 612-22	8
1050	MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. <b>2012</b> , 131, 1104-13	55
1049	Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. <b>2012</b> , 8, 549-58	16
1048	Inhibition of EKG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. <b>2012</b> , 26, 1326-38	641
1047	How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. <b>2012</b> , 12, 621-8	121
1046	Cooperative, nanoparticle-enabled thermal therapy of breast cancer. <b>2012</b> , 1, 84-9	73

1045	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. <b>2012</b> , 118, 2665-73	36
1044	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. <b>2012</b> , 118, 6188-98	10
1043	Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. <b>2012</b> , 30, 48-56	173
1042	Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. <b>2012</b> , 18, 1515-23	37
1041	Oncogenomics methods and resources. <b>2012</b> , 2012,	7
1040	Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. <b>2012</b> , 2012, 469592	70
1039	Paediatric and adult malignant glioma: close relatives or distant cousins?. <b>2012</b> , 9, 400-13	131
1038	From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. <b>2012</b> , 12, 572-8	66
1037	Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. <b>2012</b> , 18, 748-57	176
1036	Novel computational approaches to polypharmacology as a means to define responses to individual drugs. <b>2012</b> , 52, 361-79	168
1035	Targeting DNA repair and the cell cycle in glioblastoma. <b>2012</b> , 107, 463-77	28
1034	Recent advances in the molecular understanding of glioblastoma. <b>2012</b> , 108, 11-27	269
1033	An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. <b>2012</b> , 108, 29-35	43
1032	1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. <b>2012</b> , 108, 69-75	41
1031	IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. <b>2012</b> , 108, 403-10	82
1030	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <b>2012</b> , 108, 499-506	36
1029	No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. <b>2012</b> , 109, 15-22	50
1028	Clinical implications of molecular neuropathology and biomarkers for malignant glioma. <b>2012</b> , 12, 302-7	20

1027	Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. <b>2012</b> , 47, 442-7	7
1026	Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. <b>2012</b> , 69, 1507-18	50
1025	Advances in biotechnology and linking outputs to variation in complex traits: Plant and Animal Genome meeting January 2012. <b>2012</b> , 12, 1-9	5
1024	Progress in understanding 2-hydroxyglutaric acidurias. <b>2012</b> , 35, 571-87	175
1023	Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. <b>2012</b> , 22, 26-31	45
1022	Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. <b>2012</b> , 271, 111-21	147
1021	IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. <b>2012</b> , 60, 363-5	53
1020	Immunohistochemical analysis of uroplakins, urothelial-specific proteins in sinonasal Schneiderian papillomas. <b>2012</b> , 60, 365-9	
1019	Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. <b>2012</b> , 21, 297-308	2087
1018	How chemoproteomics can enable drug discovery and development. <b>2012</b> , 19, 11-22	116
1017	Tumor suppressor functions of FBW7 in cancer development and progression. <b>2012</b> , 586, 1409-18	126
1016	The enigmatic role of H2Bub1 in cancer. <b>2012</b> , 586, 1592-601	58
1015	Stratified medicine for cancer therapy. <b>2012</b> , 17, 261-8	5
1014	Targeted diazeniumdiolates: localized nitric oxide release from glioma-specific peptides and proteins. <b>2012</b> , 422, 264-70	14
1013	Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. <b>2012</b> , 39, 67-73	37
1012	Mutational determinants of epigenetic instability in myeloid malignancies. <b>2012</b> , 39, 80-96	2
1011	Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. <b>2012</b> , 136, 363-9	54
1010	IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype. <b>2012</b> , 34, 502-9	8



1009	Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas. <b>2012</b> , 120, 635-9	24
1008	IB kinase regulation of the TPL-2/ERK MAPK pathway. <b>2012</b> , 246, 168-82	99
1007	Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. <b>2012</b> , 36, 990-7	30
1006	Tumor metabolism as modulator of immune response and tumor progression. <b>2012</b> , 22, 335-41	73
1005	Long non-coding RNA expression profiles predict clinical phenotypes in glioma. <b>2012</b> , 48, 1-8	286
1004	IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. <b>2012</b> , 103, 269-73	185
1003	Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. <b>2012</b> , 103, 587-92	70
1002	Epigenetics and blood disorders. <b>2012</b> , 158, 307-22	9
1001	Review: insights gained from modelling high-grade glioma in the mouse. <b>2012</b> , 38, 254-70	15
1000	Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. <b>2012</b> , 38, 271-91	86
999	Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. <b>2012</b> , 32, 133-8	21
998	Rosette-forming glioneuronal tumor of the septum pellucidum with extension to the supratentorial ventricles: rare case with genetic analysis. <b>2012</b> , 32, 301-5	32
997	Insights into the pathogenesis of axial spondyloarthritis from network and pathway analysis. <b>2012</b> , 6 Suppl 1, S4	8
996	Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. <b>2012</b> , 51, 10-9	50
995	Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors. <b>2012</b> , 51, 429-37	23
994	Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. <b>2012</b> , 51, 480-9	50
993	IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. <b>2012</b> , 118, 452-60	71
992	The large-scale distribution of somatic mutations in cancer genomes. <b>2012</b> , 33, 136-43	56

991	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. <b>2012</b> , 33, 100-3	230
990	Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. <b>2012</b> , 33, 763-76	40
989	Aberrant DNA methylation and tumor suppressive activity of the EBF3 gene in gastric carcinoma. <b>2012</b> , 130, 817-26	21
988	Double-stranded Let-7 mimics, potential candidates for cancer gene therapy. <b>2012</b> , 68, 107-19	13
987	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. <b>2012</b> , 91, 519-25	86
986	Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. <b>2012</b> , 107, 1-12	42
985	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. <b>2012</b> , 107, 197-205	237
984	IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. <b>2013</b> , 30, 67-72	33
983	Lipidized glioblastoma: pathological and molecular characteristics. <b>2013</b> , 33, 87-92	3
982	Clinicopathological and genetic characteristics of extraventricular neurocytomas. <b>2013</b> , 33, 111-21	27
981	Integrated analysis of recurrent properties of cancer genes to identify novel drivers. <b>2013</b> , 14, R52	29
980	Targeted therapies in colorectal cancer-an integrative view by PPPM. <b>2013</b> , 4, 3	57
979	Detection of EGFRVIII mutant DNA in the peripheral blood of brain tumor patients. <b>2013</b> , 115, 27-35	33
978	A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). <b>2013</b> , 114, 309-17	29
977	Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. <b>2013</b> , 113, 251-8	21
976	Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. <b>2013</b> , 113, 277-84	51
975	GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. <b>2013</b> , 113, 65-74	63
974	Interlaboratory comparison of IDH mutation detection. <b>2013</b> , 112, 173-8	54

973	Cancer heterogeneity--a multifaceted view. <b>2013</b> , 14, 686-95	160
972	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. <b>2013</b> ,	
971	The genetics of melanoma: recent advances. <b>2013</b> , 14, 257-79	61
970	Invasion as target for therapy of glioblastoma multiforme. <b>2013</b> , 1836, 236-44	63
969	The integrated landscape of driver genomic alterations in glioblastoma. <b>2013</b> , 45, 1141-9	400
968	Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. <b>2013</b> , 23, 237-43	66
967	BCAT1 defines gliomas by IDH status. <b>2013</b> , 19, 816-7	13
966	Progress on molecular biomarkers and classification of malignant gliomas. <b>2013</b> , 7, 150-6	17
965	Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. <b>2013</b> , 61-72	
964	Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. <b>2013</b> , 15, 967-77	104
963	Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases. <b>2013</b> , 35, 602-11	29
962	Molecular Diagnostics for Neurological Disorders. <b>2013</b> , 155-210	1
961	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. <b>2013</b> , 14, 505	25
960	Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers. <b>2013</b> , 14, 440	17
959	Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. <b>2013</b> , 14, 165	28
958	The expression of cytoglobin as a prognostic factor in gliomas: a retrospective analysis of 88 patients. <b>2013</b> , 13, 247	21
957	Mitochondrial DNA, Mitochondria, Disease and Stem Cells. <b>2013</b> ,	2
956	Impact of genetic targets on cancer therapy. Forward. <b>2013</b> , 779, v-vi	1

955	Reply to Marc Scherer. <b>2013</b> , 23, 488	3
954	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and 5-HG. <b>2013</b> , 1, 18	44
953	Gliomas in children. <b>2013</b> , 15, 316-27	18
952	Deregulated chromatin remodeling in the pathobiology of brain tumors. <b>2013</b> , 15, 1-24	17
951	A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. <b>2013</b> , 260, 1469-80	21
950	Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation. <b>2013</b> , 30, 175-9	4
949	Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases. <b>2013</b> , 30, 151-9	15
948	Usefulness of immunohistochemical expression analysis of metabolic-related molecules in differentiating between intracranial neoplastic and non-neoplastic lesions. <b>2013</b> , 30, 144-50	3
947	Primary Tumors of the Nervous System. <b>2013</b> , 1-22	
946	Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma. <b>2013</b> , 34, 1139-43	3
945	Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. <b>2013</b> , 18, 1447-68	107
944	Metabolic modulation of epigenetics in gliomas. <b>2013</b> , 23, 217-21	37
943	PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. <b>2013</b> , 23, 565-73	71
942	Molecular neuro-oncology in clinical practice: a new horizon. <b>2013</b> , 14, e370-9	149
941	Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. <b>2013</b> , 98, 648-57	85
940	Transforming acidic coiled-coil proteins (TACCs) in human cancer. <b>2013</b> , 336, 24-33	41
939	Next Generation Sequencing in Cancer Research. <b>2013</b> ,	4
938	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. <b>2013</b> , 126, 277-89	36

937	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. <b>2013</b> , 16, 1373-82	306
936	Current NMR Strategies for Biomarker Discovery. <b>2013</b> , 87-117	4
935	The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. <b>2013</b> , 24, 365-78	102
934	MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. <b>2013</b> , 19, 477-83	75
933	Targeting the unfolded protein response in disease. <b>2013</b> , 12, 703-19	651
932	Genetic and epigenetic markers of gliomas. <b>2013</b> , 7, 303-313	3
931	2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. <b>2013</b> , 6, 92-8	23
930	An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. <b>2013</b> , 3, 1567-79	187
929	Fusicoccin a, a phytotoxic carbocyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases. <b>2013</b> , 6, 112-23	22
928	Emerging insights into the ependymoma epigenome. <b>2013</b> , 23, 206-9	18
927	Cytogenetic and molecular genetic study on granular cell glioblastoma: a case report. <b>2013</b> , 44, 282-8	13
926	Pattern Recognition in Bioinformatics. <b>2013</b> ,	1
925	Cancer genome landscapes. <i>Science</i> , <b>2013</b> , 339, 1546-58	33.3 5058
924	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. <b>2013</b> , 13, 1307-18	2
923	Tumor metabolism of malignant gliomas. <b>2013</b> , 5, 1469-84	49
922	Is glioblastoma an epigenetic malignancy?. <b>2013</b> , 5, 1120-39	37
921	Glioblastoma multiforme therapy and mechanisms of resistance. <b>2013</b> , 6, 1475-506	168
920	Cancer development, progression, and therapy: an epigenetic overview. <b>2013</b> , 14, 21087-113	164

919	Prognostic significance of CD147 in patients with glioblastoma. <b>2013</b> , 115, 19-26	29
918	Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. <b>2013</b> , 15, 1635-43	15
917	Targeting Cancer Metabolisms. <b>2013</b> , 159-174	
916	Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. <b>2013</b> , 50, 61-9	13
915	Modulation of oxidative stress as an anticancer strategy. <b>2013</b> , 12, 931-47	2078
914	A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-B nexus. <b>2013</b> , 73, 6563-73	60
913	Dual phenotypic transmission in Brugada syndrome. <b>2013</b> , 106, 366-72	1
912	Update in the treatment of high-grade Gliomas. <b>2013</b> , 31, 847-67	8
911	Mutational landscape and significance across 12 major cancer types. <b>2013</b> , 502, 333-339	2803
910	Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. <b>2013</b> , 15, 718-26	79
909	IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. <b>2013</b> , 9, 1923-35	46
908	Expression quantitative trait loci: present and future. <b>2013</b> , 368, 20120362	221
907	Metabolic mechanisms of epigenetic regulation. <b>2013</b> , 8, 2607-21	48
906	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. <b>2013</b> , 15, 1114-26	85
905	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. <b>2013</b> , 6, 88	170
904	The biology and clinical impact of genetic lesions in myeloid malignancies. <b>2013</b> , 122, 3741-8	37
903	Brain Tumors. <b>2013</b> , 47-59	
902	Mutations de gènes impliqués dans le métabolisme énergétique et cancer. <b>2013</b> , 15, 441-447	

901	Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. <b>2013</b> , 19, 4951-60	134
900	Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes. <b>2013</b> , 7, 101	184
899	Intra-relation reconstruction from inter-relation: miRNA to gene expression. <b>2013</b> , 7 Suppl 3, S8	10
898	Fueling immunity: insights into metabolism and lymphocyte function. <i>Science</i> , <b>2013</b> , 342, 1242454	33-3 778
897	Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. <b>2013</b> , 11, 284	16
896	Emerging patterns of somatic mutations in cancer. <b>2013</b> , 14, 703-18	366
895	Identifying New Targets for Personalised Cancer Therapy. <b>2013</b> ,	1
894	Systems Biology and Systems Medicine. <b>2013</b> , 60-72	2
893	Personalized oncology in interventional radiology. <b>2013</b> , 24, 1083-92; quiz 1093	21
892	Biomarkers in Oncology. <b>2013</b> ,	1
891	Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies. <b>2013</b> , 15, 29-42	9
890	Host genomic influences on HIV/AIDS. <b>2013</b> , 14, 201	16
889	Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to Etoposide. <b>2013</b> , 18, 286-99	23
888	Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. <b>2013</b> , 9, 637	192
887	A decision-theory approach to interpretable set analysis for high-dimensional data. <b>2013</b> , 69, 614-23	5
886	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <b>2013</b> , 110, 6021-6	968
885	Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations. <b>2013</b> , 32, 224-8	8
884	Visualizing multidimensional cancer genomics data. <b>2013</b> , 5, 9	68

883	Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. <b>2013</b> , 5, 47	35
882	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. <b>2013</b> , 5, 66	17
881	Current and future directions for Phase II trials in high-grade glioma. <b>2013</b> , 13, 369-87	4
880	Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells. <b>2013</b> , 104, 143-8	12
879	Deep sequencing in cancer research. <b>2013</b> , 43, 110-5	16
878	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. <b>2013</b> , 10, 14-26	247
877	The definition of primary and secondary glioblastoma. <b>2013</b> , 19, 764-72	640
876	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. <b>2013</b> , 11, 10	139
875	Expanding the spectrum of IDH1 mutations in gliomas. <b>2013</b> , 26, 619-25	29
874	Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. <b>2013</b> , 73, 496-501	99
873	Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and Eatenin. <b>2013</b> , 15, 42-50	18
872	Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. <b>2013</b> , 61, 25-41	145
871	A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. <b>2013</b> , 47, 131-44	205
870	Theoretical and computational studies of dendrimers as delivery vectors. <b>2013</b> , 42, 705-27	175
869	Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. <b>2013</b> , 22, 84-95	38
868	Genetics and pharmacogenomics of diffuse gliomas. <b>2013</b> , 137, 78-88	6
867	Epigenetic therapy of hematological malignancies: where are we now?. <b>2013</b> , 4, 81-91	23
866	Biomarker Discovery Strategies: DNA, RNA, and Protein. <b>2013</b> , 401-416	



865	Classification of mitocans, anti-cancer drugs acting on mitochondria. <b>2013</b> , 13, 199-208	163
864	TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. <b>2013</b> , 15, 29-40	52
863	Glioblastoma: molecular analysis and clinical implications. <b>2013</b> , 64, 59-70	75
862	Diagnostic applications of high-throughput DNA sequencing. <b>2013</b> , 8, 381-410	45
861	Clinicopathological features of human brainstem gliomas. <b>2013</b> , 30, 1-7	18
860	Enhanced-acceptor fluorescence-based single cell ATP biosensor monitors ATP in heterogeneous cancer populations in real time. <b>2013</b> , 35, 175-80	12
859	Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. <b>2013</b> , 340, 247-53	46
858	The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. <b>2013</b> , 288, 3804-15	116
857	IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. <b>2013</b> , 15, 469-79	130
856	Mitochondrial dysfunction in gliomas. <b>2013</b> , 20, 216-27	24
855	Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro. <b>2013</b> , 319, 2037-2048	29
854	Cytoplasmic TRADD confers a worse prognosis in glioblastoma. <b>2013</b> , 15, 888-97	12
853	Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. <b>2013</b> , 11, 199-206	6
852	A case of oligodendroglioma with prominent neuronal differentiation. <b>2013</b> , 44, 2353-9	9
851	GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. <b>2013</b> , 329, 27-36	23
850	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. <b>2013</b> , 81, 1515-22	160
849	The molecular biology of WHO grade II gliomas. <b>2013</b> , 34, E1	15
848	Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. <b>2013</b> , 432, 40-5	22

847	Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation. <b>2013</b> , 433, 374-8	12
846	Brain-derived neurotrophic factor plus vascular endothelial growth factor additively promotes early growth of the transitional cell carcinoma cell line BFTC905 in vitro and in vivo. <b>2013</b> , 25, 155-160	2
845	Oncology scan--low-grade gliomas: predicting and changing outcome. <b>2013</b> , 87, 234-6	4
844	A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. <b>2013</b> , 432, 564-7	15
843	Incorporation of prognostic and predictive factors into glioma clinical trials. <b>2013</b> , 15, 56-63	30
842	Tumor prognostic factors and the challenge of developing predictive factors. <b>2013</b> , 15, 33-46	1
841	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. <b>2013</b> , 45, 253-61	231
840	Preclinical Development of Oncology Drugs. <b>2013</b> , 543-565	1
839	The effect of one additional driver mutation on tumor progression. <b>2013</b> , 6, 34-45	26
838	Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. <b>2013</b> , 1, 3	166
837	Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. <b>2013</b> , 23, 210-6	64
836	Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. <b>2013</b> , 14, 81-9	90
835	Surgical resection of malignant gliomas-role in optimizing patient outcome. <b>2013</b> , 9, 141-51	106
834	CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. <b>2013</b> , 152, 1077-90	113
833	MicroRNA-183 upregulates HIF-1 $\alpha$ by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. <b>2013</b> , 111, 273-83	68
832	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. <b>2013</b> , 15, 57-68	105
831	Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?. <b>2013</b> , 779, 267-89	11
830	Classification of Gliomas. <b>2013</b> , 3-20	

829	The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. <b>2013</b> , 12, 449-58	68
828	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. <b>2013</b> , 98, E364-9	157
827	SnapShot: cancer metabolism pathways. <b>2013</b> , 17, 466-466.e2	37
826	Impact of deleterious passenger mutations on cancer progression. <b>2013</b> , 110, 2910-5	210
825	Epigenomics: sequencing the methylome. <b>2013</b> , 973, 39-54	2
824	The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. <b>2013</b> , 34, 849-62	40
823	Sum of the parts: mass spectrometry-based metabolomics. <b>2013</b> , 52, 3829-40	48
822	Genetic and epigenetic alterations of myeloproliferative disorders. <b>2013</b> , 97, 183-97	47
821	Epigenetics and Brain Cancer. <b>2013</b> , 21-40	
820	Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. <b>2013</b> , 31, 190-202	23
819	How molecular testing can help (and hurt) in the workup of gliomas. <b>2013</b> , 139, 275-88	4
818	From systems to structure: bridging networks and mechanism. <b>2013</b> , 49, 222-31	30
817	Paediatric spinal glioblastoma: case report and review of therapeutic strategies. <b>2013</b> , 29, 367-74	9
816	Lessons from the cancer genome. <b>2013</b> , 153, 17-37	912
815	The Molecular Biology of Diffuse Low-Grade Gliomas. <b>2013</b> , 99-115	
814	Materials science: The same, but better. <b>2013</b> , 496, 40-1	
813	Cancer: A metabolic metamorphosis. <b>2013</b> , 496, 38-40	9
812	Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. <b>2013</b> , 45, 602-12	562

811	High frequency of temperature-sensitive mutants of p53 in glioblastoma. <b>2013</b> , 19, 421-8		6
810	Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients. <b>2013</b> , 49, 567-73		7
809	IDH1 mutations in oligodendroglial tumors: comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR. <b>2013</b> , 23, 285-93		21
808	A comparative study of short- and long-TE <sup>1</sup> H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. <b>2013</b> , 26, 1242-50		63
807	Genomics and epigenomics of colorectal cancer. <b>2013</b> , 5, 205-19		25
806	What do we know about IDH1/2 mutations so far, and how do we use it?. <b>2013</b> , 125, 621-36		100
805	IDH1 and IDH2 mutations in gliomas. <b>2013</b> , 13, 345		347
804	Anaplastic astrocytoma. <b>2013</b> , 15, 302-15		6
803	PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability. <b>2013</b> , 346, 91-7		25
802	The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. <b>2013</b> , 32, 3840-5		37
801	The Role of Mitochondrial DNA in Tumorigenesis. <b>2013</b> , 119-155		
800	Human Low-Grade Glioma Cultures. <b>2013</b> , 137-163		3
799	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. <i>Science</i> , <b>2013</b> , 340, 626-30	33-3	855
798	Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. <b>2013</b> , 34, 1991-2002		96
797	Mitochondrial complex II, a novel target for anti-cancer agents. <b>2013</b> , 1827, 552-64		78
796	Understanding genomic alterations in cancer genomes using an integrative network approach. <b>2013</b> , 340, 261-9		49
795	Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. <b>2013</b> , 336, 299-306		22
794	Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. <b>2013</b> , 4, 542-546		62

793	Mutational heterogeneity in cancer and the search for new cancer-associated genes. <b>2013</b> , 499, 214-218	3616
792	Cancer metabolism: key players in metabolic reprogramming. <b>2013</b> , 104, 275-81	166
791	Systems biology for molecular life sciences and its impact in biomedicine. <b>2013</b> , 70, 1035-53	20
790	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. <b>2013</b> , 125, 659-69	201
789	Tumor Biology and Metastasis. <b>2013</b> , 30-50	1
788	Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. <b>2013</b> , 126, 21-37	13
787	Subgrouping of gliomas on the basis of genetic profiles. <b>2013</b> , 30, 203-8	25
786	Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C. <b>2017</b> , 127, 4554-4568	15
785	How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?. <b>2012</b> , 2012, 28-34	24
784	Cancer genome landscape: a radiologist's guide to cancer genome medicine with imaging correlates. <b>2019</b> , 10, 111	2
783	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. <b>2019</b> , 9, 110	1
782	Integrative Sparse -Means With Overlapping Group Lasso in Genomic Applications for Disease Subtype Discovery. <b>2017</b> , 11, 1011-1039	18
781	Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. <b>2009</b> , 11, 779-89	47
780	Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. <b>2009</b> , 11, 779-789	61
779	IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. <b>2014</b> , 20, 247-54	10
778	EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. <b>2015</b> , 40, 739-749	22
777	Absence of AKT1 mutations in glioblastoma. <b>2009</b> , 4, e5638	14
776	Bi-directional SIFT predicts a subset of activating mutations. <b>2009</b> , 4, e8311	27

775	Evidence of genetic instability in tumors and normal nearby tissues. <b>2010</b> , 5, e9343	2
774	A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. <b>2011</b> , 6, e18583	86
773	Somatic mutagenesis with a Sleeping Beauty transposon system leads to solid tumor formation in zebrafish. <b>2011</b> , 6, e18826	24
772	Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. <b>2011</b> , 6, e20041	111
771	Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. <b>2011</b> , 6, e20588	29
770	Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. <b>2011</b> , 6, e22000	11
769	The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. <b>2011</b> , 6, e26737	22
768	The temporal order of genetic and pathway alterations in tumorigenesis. <b>2011</b> , 6, e27136	76
767	Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. <b>2011</b> , 6, e27484	27
766	Cancer gene prioritization for targeted resequencing using FitSNP scores. <b>2012</b> , 7, e31333	2
765	Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. <b>2012</b> , 7, e31884	13
764	Microfluidic synthesis of microfibers for magnetic-responsive controlled drug release and cell culture. <b>2012</b> , 7, e33184	49
763	Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. <b>2012</b> , 7, e35262	55
762	Personalized pathway enrichment map of putative cancer genes from next generation sequencing data. <b>2012</b> , 7, e37595	10
761	miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2. <b>2012</b> , 7, e39818	50
760	Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. <b>2012</b> , 7, e42818	32
759	Somatic mutations of PIK3R1 promote gliomagenesis. <b>2012</b> , 7, e49466	40
758	Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. <b>2013</b> , 8, e53310	31

757	MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. <b>2013</b> , 8, e53765	50
756	The spectrum of SWI/SNF mutations, ubiquitous in human cancers. <b>2013</b> , 8, e55119	351
755	High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. <b>2013</b> , 8, e56185	21
754	Distinct genomic aberrations between low-grade and high-grade gliomas of Chinese patients. <b>2013</b> , 8, e57168	20
753	Modulation of HJURP (Holliday Junction-Recognizing Protein) levels is correlated with glioblastoma cells survival. <b>2013</b> , 8, e62200	31
752	Cancer missense mutations alter binding properties of proteins and their interaction networks. <b>2013</b> , 8, e66273	69
751	Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival. <b>2013</b> , 8, e67421	23
750	IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. <b>2013</b> , 8, e68782	74
749	Acetate supplementation induces growth arrest of NG2/PDGFR $\beta$ positive oligodendroglioma-derived tumor-initiating cells. <b>2013</b> , 8, e80714	13
748	Identification of novel genetic alterations in samples of malignant glioma patients. <b>2013</b> , 8, e82108	26
747	Identification of mutations in distinct regions of p85 alpha in urothelial cancer. <b>2013</b> , 8, e84411	11
746	Molecular subtypes of glioblastoma are relevant to lower grade glioma. <b>2014</b> , 9, e91216	67
745	A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins. <b>2014</b> , 9, e95216	63
744	A unique four-hub protein cluster associates to glioblastoma progression. <b>2014</b> , 9, e103030	22
743	Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication. <b>2014</b> , 9, e115025	4
742	Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach. <b>2014</b> , 9, e115687	19
741	Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. <b>2015</b> , 10, e0124178	15
740	A Novel Type II NAD <sup>+</sup> -Specific Isocitrate Dehydrogenase from the Marine Bacterium <i>Congregibacter litoralis</i> KT71. <b>2015</b> , 10, e0125229	8

739	Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin. <b>2015</b> , 10, e0125791	21
738	Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. <b>2015</b> , 10, e0130872	16
737	Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors. <b>2015</b> , 10, e0137259	10
736	PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas. <b>2015</b> , 10, e0142750	9
735	On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. <b>2016</b> , 11, e0147794	10
734	MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. <b>2016</b> , 11, e0156422	12
733	Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis in Human Glioblastoma Cells. <b>2016</b> , 11, e0159092	14
732	MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. <b>2016</b> , 11, e0165107	18
731	Somatic Variations in Cervical Cancers in Indian Patients. <b>2016</b> , 11, e0165878	6
730	Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme. <b>2017</b> , 12, e0185208	10
729	The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis. <b>2016</b> , 8, 29-39	11
728	Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer. <b>2019</b> , 26, R319-R344	13
727	Molecular Genetics of Secondary Glioblastoma. 27-42	8
726	Mitochondria in cancer. <b>2020</b> , 4, 114-146	59
725	IDH1 mutations in a Brazilian series of Glioblastoma. <b>2011</b> , 66, 163-5	22
724	Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas. <b>2020</b> , 20, 63-69	7
723	The History of Neuroscience and Neurosurgery in Japan. <b>2015</b> , 1, 31-40	3
722	In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation. <b>2016</b> , 2, 311-329	5



721	Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <b>2015</b> , 1, 37-43	9
720	Improved localisation for 2-hydroxyglutarate detection at 3T using long-TE semi-LASER. <b>2016</b> , 2, 94-105	17
719	Characterization of an Orthotopic Rat Model of Glioblastoma Using Multiparametric Magnetic Resonance Imaging and Bioluminescence Imaging. <b>2018</b> , 4, 55-65	6
718	Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma. <b>2019</b> , 11, 12246-12269	44
717	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. <b>2020</b> , 12, 16155-16171	1
716	Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients. <b>2020</b> , 12, 18297-18321	10
715	Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer. <b>2015</b> , 2, 483-6	14
714	Single-cell analyses of transcriptional heterogeneity in squamous cell carcinoma of urinary bladder. <b>2016</b> , 7, 66069-66076	23
713	Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme. <b>2016</b> , 7, 79572-79583	13
712	TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection. <b>2016</b> , 7, 81512-81526	38
711	IGFBP2 expression predicts IDH-mutant glioma patient survival. <b>2017</b> , 8, 191-202	25
710	Integrated genomic analyses identify ERFF1 and TACC3 as glioblastoma-targeted genes. <b>2010</b> , 1, 265-77	79
709	The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. <b>2017</b> , 8, 2083-2095	11
708	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. <b>2013</b> , 4, 1737-47	119
707	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. <b>2013</b> , 4, 1729-36	171
706	Small G protein Rac GTPases regulate the maintenance of glioblastoma stem-like cells in vitro and in vivo. <b>2017</b> , 8, 18031-18049	23
705	Molecular markers of paragangliomas/pheochromocytomas. <b>2017</b> , 8, 25756-25782	26
704	Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival. <b>2017</b> , 8, 50117-50123	58

703	MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations. <b>2017</b> , 8, 25345-25361	17
702	IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. <b>2017</b> , 8, 28865-28879	12
701	Association between tumor architecture derived from generalized Q-space MRI and survival in glioblastoma. <b>2017</b> , 8, 41815-41826	7
700	Identification of driver modules in pan-cancer via coordinating coverage and exclusivity. <b>2017</b> , 8, 36115-36126	6
699	In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. <b>2017</b> , 8, 49165-49177	44
698	Prognostic value of DNA repair genes based on stratification of glioblastomas. <b>2017</b> , 8, 58222-58230	9
697	Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. <b>2017</b> , 8, 45888-45897	28
696	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. <b>2014</b> , 5, 1515-25	187
695	PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma. <b>2017</b> , 8, 46348-46362	28
694	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. <b>2014</b> , 5, 2551-61	55
693	Targeting metabolic remodeling in glioblastoma multiforme. <b>2010</b> , 1, 552-62	149
692	Cofilin-1 and phosphoglycerate kinase 1 as promising indicators for glioma radiosensitivity and prognosis. <b>2017</b> , 8, 55073-55083	5
691	CDK4/6 inhibition is more active against the glioblastoma proneural subtype. <b>2017</b> , 8, 55319-55331	23
690	Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas. <b>2014</b> , 5, 6003-14	8
689	Mutational analysis of primary central nervous system lymphoma. <b>2014</b> , 5, 5065-75	119
688	Remote intracranial recurrence of mutant gliomas is associated with mutations and an 8q gain. <b>2017</b> , 8, 84729-84742	7
687	The NF1 gene revisited - from bench to bedside. <b>2014</b> , 5, 5873-92	91
686	The molecular classification of astrocytic tumors. <b>2017</b> , 8, 96340-96350	7

685	WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of gene expression. <b>2017</b> , 8, 106352-106368	1
684	Impact of (rs2071543) gene polymorphism in increasing cancer risk: evidence from a meta-analysis and trial sequential analysis. <b>2018</b> , 9, 6572-6585	6
683	The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. <b>2018</b> , 9, 10497-10509	10
682	Virus and tumor microenvironment induced ER stress and unfolded protein response: from complexity to therapeutics. <b>2018</b> , 9, 31920-31936	7
681	IDH1 is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment. <b>2018</b> , 9, 35100-35113	7
680	Oncogenic is differentially regulated in wild-type vs. mutant gliomas. <b>2018</b> , 9, 37097-37111	3
679	End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. <b>2014</b> , 5, 12769-87	22
678	Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. <b>2019</b> , 10, 3641-3653	1
677	The predictive capability of immunohistochemistry and DNA sequencing for determining functional mutation status: a comparative study of 41 glioblastoma patients. <b>2019</b> , 10, 6204-6218	7
676	Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies. <b>2020</b> , 11, 4544-4553	2
675	New insights into the genetics of glioblastoma multiforme by familial exome sequencing. <b>2015</b> , 6, 5918-31	19
674	PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. <b>2015</b> , 6, 4790-803	29
673	Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. <b>2011</b> , 2, 833-49	88
672	Enhanced tumorigenicity by mitochondrial DNA mild mutations. <b>2015</b> , 6, 13628-43	36
671	MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). <b>2015</b> , 6, 16215-26	44
670	In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. <b>2015</b> , 6, 20145-59	16
669	Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. <b>2015</b> , 6, 17354-65	36
668	Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. <b>2012</b> , 3, 67-77	11

667	Neoplastic cells are a rare component in human glioblastoma microvasculature. <b>2012</b> , 3, 98-106	65
666	Biomarker-based prognostic stratification of young adult glioblastoma. <b>2016</b> , 7, 5030-41	34
665	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. <b>2015</b> , 6, 40896-906	91
664	Mutant IDH1 is required for IDH1 mutated tumor cell growth. <b>2012</b> , 3, 774-82	35
663	Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore. <b>2015</b> , 6, 37647-62	22
662	Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. <b>2015</b> , 6, 43452-71	47
661	FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. <b>2012</b> , 3, 1146-57	18
660	Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. <b>2012</b> , 3, 1194-203	200
659	Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells. <b>2016</b> , 7, 9907-24	14
658	Survival kinase genes present prognostic significance in glioblastoma. <b>2016</b> , 7, 20140-51	39
657	PRG3 induces Ras-dependent oncogenic cooperation in gliomas. <b>2016</b> , 7, 26692-708	6
656	IDH-1R132H mutation status in diffuse glioma patients: implications for classification. <b>2016</b> , 7, 31393-400	24
655	NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. <b>2016</b> , 7, 41251-41264	51
654	Exomic sequencing of four rare central nervous system tumor types. <b>2013</b> , 4, 572-83	57
653	Prostate cancer and the unfolded protein response. <b>2016</b> , 7, 54051-54066	35
652	Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma. <b>2018</b> , 5,	13
651	In search of effective therapies to overcome resistance to Temozolomide in brain tumours.. <b>2019</b> , 2, 1018-1031	3
650	Novel approaches to combat chemoresistance against glioblastomas.. <b>2020</b> , 3, 686-698	3

649	IDH mutational status and the immune system in gliomas: a tale of two tumors?. <b>2017</b> , 6, S1253-S1256	9
648	MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS. <b>2019</b> , 18, 34-44	1
647	Querying NeXtProt Nanopublications and Their Value for Insights on Sequence Variants and Tissue Expression.	2
646	Cold Atmospheric Plasma as a Novel Therapeutic Tool for the Treatment of Brain Cancer. <b>2020</b> , 26, 2195-2206	3
645	The mutator phenotype in cancer: molecular mechanisms and targeting strategies. <b>2010</b> , 11, 1296-303	32
644	Gene therapy and targeted toxins for glioma. <b>2011</b> , 11, 155-80	57
643	Malignant Intracranial High Grade Glioma and Current Treatment Strategy. <b>2019</b> , 19, 101-108	4
642	Untangling the Metabolic Reprogramming in Brain Cancer: Discovering Key Molecular Players Using Mass Spectrometry. <b>2019</b> , 19, 1521-1534	10
641	Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment. <b>2017</b> , 15, 116-128	58
640	Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. <b>2019</b> , 16, 861-867	2
639	Overview on current treatment standards in high-grade gliomas. <b>2018</b> , 62, 225-238	9
638	Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas. <b>2020</b> , 91, 61-78	5
637	Current practices and guidelines for clinical next-generation sequencing oncology testing. <b>2016</b> , 13, 3-11	38
636	Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation. <b>2020</b> , 21, 755-760	2
635	Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report. <b>2018</b> , 131, 1829-1834	3
634	Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications. <b>2019</b> , 1-9	28
633	Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. <b>2019</b> , 1-10	14
632	Molecular Biomarkers of Brain and Spinal Cord Astrocytomas. <b>2019</b> , 11, 17-27	7

631	Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. <b>2016</b> , 59, 44-51	3
630	Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. <b>2018</b> , 61, 319-332	16
629	Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?. <b>2012</b> , 3, 188	13
628	Non-Thermal Atmospheric Pressure Bio-Compatible Plasma Stimulates Apoptosis via p38/MAPK Mechanism in U87 Malignant Glioblastoma. <b>2020</b> , 12,	25
627	Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity. <b>2020</b> , 12,	9
626	Decoding key nodes in the metabolism of cancer cells: sugar & spice and all things nice. <b>2012</b> , 4, 2	26
625	Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?. <b>2014</b> , 20, 12391-406	43
624	Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. <b>2016</b> , 22, 2071-80	8
623	Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors. <b>2020</b> , 26, 5074-5089	5
622	Tubeimoside-1 induces apoptosis in human glioma U251 cells by suppressing PI3K/Akt-mediated signaling pathways. <b>2020</b> , 22, 1527-1535	3
621	Wild-type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells. <b>2020</b> , 22, 1949-1957	4
620	Next generation DNA sequencing of atypical choroid plexus papilloma of brain: Identification of novel mutations in a female patient by Ion Proton. <b>2019</b> , 18, 5063-5076	6
619	IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR. <b>2020</b> , 19, 1322-1330	8
618	EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma. <b>2020</b> , 20, 384	2
617	Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. <b>2012</b> , 1, 22-34	71
616	An improved understanding of cancer genomics through massively parallel sequencing. <b>2014</b> , 3, 243-259	8
615	Current trends in the surgical management and treatment of adult glioblastoma. <b>2015</b> , 3, 121	108
614	Metabolic Signaling to Epigenetic Alterations in Cancer. <b>2018</b> , 26, 69-80	20

613	Evaluation of rs1957106 Polymorphism of NF- $\kappa$ B1 in Glioblastoma Multiforme in Isfahan, Iran. <b>2019</b> , 8, 9	3
612	A contemporary molecular view of diffuse gliomas with implications for diagnosis. <b>2020</b> , 3, 38	1
611	No association between isocitrate dehydrogenase 1 mutation and increased survival of glioblastoma: A meta-analysis. <b>2020</b> , 11, 1	1
610	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. <b>2019</b> , 51, 737-747	25
609	The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. <b>2013</b> , Suppl 5,	16
608	The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. <b>2014</b> , 05, 929-945	9
607	Telomere Maintenance Mechanisms: Prognostic and Therapeutic Implications for the Pathologist and Oncologist. <b>2013</b> , 03, 10-20	2
606	Ion channels in glioblastoma. <b>2011</b> , 2011, 590249	48
605	A robust topology-based algorithm for gene expression profiling. <b>2012</b> , 2012, 381023	6
604	Clinical neuropathology practice guide 1-2013: molecular subtyping of glioblastoma: ready for clinical use?. <b>2013</b> , 32, 5-8	2
603	Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. <b>2011</b> , 44, 158-64	46
602	Transcriptome analysis reveals distinct gene expression profiles in astrocytoma grades II-IV. <b>2017</b> , 161, 261-271	3
601	Molecular diagnostics of gliomas. <b>2011</b> , 135, 558-68	55
600	Cancer stem cells and addicted cancer cells. <b>2013</b> , 1, 7	2
599	Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. <b>2013</b> , 14, 7261-4	14
598	IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo. <b>2014</b> , 15, 427-32	30
597	Lack of sunlight exposure influence on primary glioblastoma survival. <b>2014</b> , 15, 4165-8	2
596	Detection of PIK3CA gene mutations with HRM analysis and association with IGF1P-5 expression levels in breast cancer. <b>2014</b> , 15, 9327-33	8

595	Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. <b>2014</b> , 15, 10893-8	12
594	Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status. <b>2015</b> , 16, 3355-60	14
593	Data Mining for Identification of Molecular Targets in Ovarian Cancer. <b>2016</b> , 17, 1691-9	4
592	Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases. <b>2017</b> , 6,	17
591	DGPathinter: a novel model for identifying driver genes via knowledge-driven matrix factorization with prior knowledge from interactome and pathways. 3, e133	3
590	Reproducibility of SNV-calling in multiple sequencing runs from single tumors. <b>2016</b> , 4, e1508	2
589	Diagnostic performance of clinical properties and conventional magnetic resonance imaging for determining the mutation status in glioblastoma: a retrospective study. <b>2019</b> , 7, e7154	5
588	A preoperative risk classifier that predicts tumor progression in patients with cranial base chondrosarcomas. <b>2020</b> , 1-9	3
587	Cytoglobin as a Prognostic Factor for Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis of 75 Patients. <b>2021</b> , 50, 994-999	
586	Detecció de la mutació de la enzima isocitrato deshidrogenasa en gliomas difusos grados II, III y IV. <b>2021</b> , 25, 709-719	
585	Identification of five important genes to predict glioblastoma subtypes. <b>2021</b> , 3, vdab144	1
584	Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B -shim array coils at 3 T. <b>2021</b> , e4621	
583	YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. <b>2021</b> , 134,	1
582	Longitudinal Bottom-Up Proteomics of Serum, Serum Extracellular Vesicles, and Cerebrospinal Fluid Reveals Candidate Biomarkers for Early Detection of Glioblastoma in a Murine Model. <b>2021</b> , 26,	2
581	Predicting Overall Survival Time in Glioblastoma Patients Using Gradient Boosting Machines Algorithm and Recursive Feature Elimination Technique. <b>2021</b> , 13,	1
580	Emerging applications of imaging in glioma: focus on PET/MRI and radiomics. <b>2021</b> , 9, 609	
579	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. <b>2022</b> , 36, 95-111	1
578	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. <b>2021</b> ,	11



- 577 Transcriptomic Analysis Identified Two Subtypes of Brain Tumor Characterized by Distinct Immune Infiltration and Prognosis. **2021**, 11, 734407 1
- 576 Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses. **2021**, 144, 112278 3
- 575 Combinatorial Therapeutic Strategies for Blocking Kinase Pathways in Brain Tumors. **2009**, 953-975
- 574 An Integrated Genomic Analysis of Human Glioblastoma Multiforme. **2009**, 2009, 115-116 1
- 573 The  $Nf1^{\Delta/+}; Trp53^{\Delta/+}$  cis Mouse Model of Anaplastic Astrocytoma and Secondary Glioblastoma: Dissecting Genetic Susceptibility to Brain Cancer. **2009**, 93-118 1
- 572 Epigenetic Profiling of Gliomas. **2009**, 615-650 1
- 571 Stat3 Oncogenic Signaling in Glioblastoma Multiforme. **2009**, 899-918
- 570 Microarray and Proteomic Analysis of Gliomas: Target Strategies. **2009**, 179-196
- 569 Personalized Therapy for Cancer. **2009**, 165-254
- 568 mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside. **2009**, 99-111
- 567 Discovery of Genetic Markers for Brain Tumors by Comparative Genomic Hybridization. **2009**, 373-394
- 566 Recent Advances in Cancer Genomics and Cancer-Associated Genes Discovery. **2010**, 11-29
- 565 New therapies for recurrent glioblastomas. **2009**, 1,
- 564 Science Signaling Podcast: 15 December 2009. **2009**, 2,
- 563 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. **2010**, 2010, 111-112
- 562 Analysis of Inherited and Acquired Genetic Variation. **2010**, 13-31
- 561 Recent Advances in Biological Research on Malignant Glioma and Their Therapeutic Relevance(Progress in Treatment for Malignant Gliomas). **2010**, 19, 880-886 1
- 560 Cancer Targets. **2010**, 115-128

559 Genomics Data Analysis Pipelines. **2010**, 117-137

558 [Identifying candidate cancer genes based on co-evolving gene modules]. **2010**, 32, 694-700

557 Clinical implications of next-generation sequencing for cancer medicine. **2010**, 17, 39-42

7

556 High-Grade Astrocytomas. **2011**, 195-232

555 Cancer Genome Sequencing.

554 MicroRNAs in Brain Tumors. **2011**, 343-371

553 Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations. **2011**, 53-62

552 The Hallmarks of Cancer Revisited Through Systems Biology and Network Modelling. **2011**, 245-266

1

551 Glioblastoma: Germline Mutation of TP53. **2011**, 31-38

550 Gliomagenesis: Advantages and Limitations of Biomarkers. **2011**, 11-24

0

549 Molecular Genetic Pathology of Solid Tumors. **2011**, 1441-1462

548 Malignant Gliomas. **2011**, 1327-1340

547 The Genetic Origins of Brain Tumors. **2011**, 1133-1140

546 Non-Cytogenetic Markers and their Impact on Prognosis. 56-76

545 Brain Tumors. **2011**, 1075-1076

544 Molecular Genetics and the Development of Targets for Glioma Therapy. **2011**, 1112-1123

543 Cancer and Signaling Pathway Deregulation. **2011**, 369-379

542 Brain Tumours.

- 541 Tumorigenesis of Glioma-Initiating Cells: Role of Sox11. **2012**, 93-98
- 540 Biomarkers of System Response to Therapeutic Intervention.
- 539 Cancer Stem Cells and the Central Nervous System. **2012**, 105-121
- 538 DNA Damage Checkpoint Signaling Pathways in Human Cancer. **2012**, 23-37
- 537 Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms. **2012**, 131-145
- 536 Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. **2012**, 183-240
- 535 Signaling the Unfolded Protein Response in cancer. **2012**, 357-382
- 534 Cancer and the Nervous System. **2012**, 1116-1136
- 533 UPR Activation in Cancer Cells: A Double-Edged Sword. **2012**, 383-412
- 532 Somatic Copy Number Alterations: Gene and Protein Expression Correlates in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. **2012**, 405-428
- 531 Development and Clinical Implementation of Reverse Phase Protein Microarrays for Protein Network Activation Mapping: Personalized Cancer Therapy. **2012**, 309-323
- 530 Pediatric Brain Tumors: Application of Stratification Criteria to Refine Patient Management. **2012**, 211-222 1
- 529 Genetic Analysis and Direction of Basic Research in Glioma(Current Status and Perspectives of Treatment for Glioma). **2012**, 21, 216-223 0
- 528 Children Are Not Small Adults: Importance of Molecular Analysis for Diagnosis, Prognosis, and Treatment of Pediatric CNS Tumors. **2012**, 125-140
- 527 Supratentorial Primitive Neuroectodermal Tumor: Biology. **2012**, 77-83
- 526 Oncogenic driver mutations. **2012**, 45-58
- 525 Pathogenesis, molecular characteristics and prognostic factors for survival. **2012**, 6-15
- 524 Primary Cilia and Brain Cancer. **2013**, 209-228

- 523 Multiple functions of a glioblastoma fusion oncogene. **2013**, 123, 548-51 4
- 522 Molecular markers of glioma initiating cells. **2013**, 33, 181-189
- 521 Update on Glioma Treatments in the United States. **2013**, 22, 590-596
- 520 Is Gliomatosis Cerebri a Diffuse Low-Grade Glioma?. **2013**, 45-59
- 519 Suppression of Cellular Senescence in Glioblastoma: Role of Src Homology Domain-Containing Phosphatase 2. **2013**, 249-259
- 518 TYPES OF DNA DAMAGE. **2013**, 115-118
- 517 Comprehensive Genomic Alterations in Common Cancer Cell Lines Revealed by Exome Sequencing. **2013**, 165-182
- 516 Colorectal Cancer Genome and Its Implications. **2013**, 247-265
- 515 Identification and Characterization of a Human ProstateCancer Specific Long Non-Coding RNA. **2013**, 1-4
- 514 Animal Models for Low-Grade Gliomas. **2013**, 165-175
- 513 Pitfalls in experimental designs for characterizing the transcriptional, methylational and copy number changes of oncogenes and tumor suppressor genes. **2013**, 8, e58163 1
- 512 Bridging science and clinical practice: how to use molecular markers when caring for a patient with brain cancer. **2013**, 108-13
- 511 Molecular Diagnosis of Cancer. **2014**, 249-346 1
- 510 Statistical tools and R software for cancer driver probabilities. **2014**, 1101, 113-34
- 509 Heat-Shock Protein-Based Cancer Immunotherapy. **2014**, 37-56
- 508 Basic Cancer Biology. **2014**, 1-39
- 507 Metabolic Adaptation in Reprogrammed Cancer Cells. **2014**, 157-180
- 506 Molecular Testing in CNS tumors. **2014**, 243-255

505 LGR5 as a Marker in Brain Cancer. **2014**, 1-14

504 Helping Students Respond Creatively to a Complex World. **2014**, 249-268

503 Autophagy in Glioma Cells. **2014**, 117-149

502 Gene Expression in HNC. **2014**, 325-341

1

501 Novel Strategies in Chemotherapy for Gliomas. **2015**, 24, 386-398

500 High-Grade Glioma. **2015**, 101-116

499 LGR5 as Marker in Brain Cancer. **2015**, 361-378

498 Fighting Fire with Fire in Cancer. **2015**, 39-49

0

497 Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models. **2015**, 341-354

496 Refined Glioma Classification based on Molecular Pathology. **2015**, 24, 366-377

495 Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation. **2015**, 16, 4095-101

3

494 Central nervous system. 706-725

493 Dynamical studies of cellular signaling networks in cancers. **2016**, 65, 178704

3

492 Mismatch Repair. **2016**, 305-339

0

491 IDH1 (Isocitrate Dehydrogenase 1). **2016**, 1-5

490 Chemotherapeutics and Their Efficacy. **2016**, 133-141

489 Subcellular Protein Localisation in Health and Disease. 1-7

488 Dysregulated Signaling Pathways in Glioblastoma Cancer Stem-Like Cells: Potential Targets for Therapeutic Intervention. **2016**, 3,

- 487 Synthesis and Application of Cell-Permeable Metabolites for Modulating Chromatin Modifications Regulated by  $\alpha$ -Ketoglutarate-Dependent Enzymes. **2017**, 63-79
- 486 Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study. **2017**, 11, BC05-BC08
- 485 CpG Island Methylator Phenotype in Cancer. 1-10
- 484 Molecular Testing for Glioblastoma. **2017**, 339-347
- 483 Central Nervous System. 706-725
- 482 Direct in vivo mapping of functional suppressors in glioblastoma genome.
- 481 Cancer Metabolism. **2018**, 129-154
- 480 Chromatin run-on reveals the transcriptional etiology of glioblastoma multiforme. 3
- 479 Intratumoral Heterogeneity of Tumor Infiltration of Glioblastoma Revealed by Joint Histogram Analysis of Diffusion Tensor Imaging.
- 478 Multi-Parametric and Multi-Regional Histogram Analysis of MRI: Revealing Imaging Phenotypes of Glioblastoma Correlated with Patient Survival.
- 477 Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. **2018**, 1-44
- 476 Multi-target analysis of neoplasms for the evaluation of tumor progression: stochastic approach of biologic processes. **2018**, 5, 14-62
- 475 Targeted therapy in cancer. **2018**, 3, 13
- 474 High-Grade Gliomas. **2018**, 580-585.e2
- 473 Cerebral Gliomas. **2018**, 1-29 0
- 472 Low-Grade Glioma. **2018**, 65-82
- 471 The Functional Genomic Circuitry of Human Glioblastoma Stem Cells.
- 470 MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2.

- 469 Encyclopedia of Signaling Molecules. **2018**, 2506-2510
- 468 MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2.
- 467 Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced de-novo mutation in survival outliers of glioblastoma.
- 466 The functional genomic circuitry of human glioblastoma stem cells.
- 465 Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition.
- 464 EXPOsOMICs: Meet-in-the-Middle and Network Perturbation. **2019**, 349-392
- 463 Therapeutic Strategy for Glioma Grade II/III. **2019**, 28, 699-704
- 462 Most of transcriptional alterations in glioma result from DNA-methylation independent mechanisms.
- 461 Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate. **2019**, 1
- 460 Targeting Mitochondrial Enzymes in Pancreatic Cancer. **2019**, 95-110
- 459 [Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis]. **2019**, 83, 17-26 2
- 458 Metabolic Deregulations Affecting Chromatin Architecture: One-Carbon Metabolism and Krebs Cycle Impact Histone Methylation. **2019**, 573-606 1
- 457 CircNT5E/miR-422a: a new circRNA-based ceRNA network in glioblastoma.. **2019**, 8, S106-S109
- 456 Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.
- 455 Patterns of local failure in patients with high-grade glioma after postoperative radiotherapy with or without chemotherapy.. **2019**, 8, 985-991
- 454 The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis. **2019**, 36, 222-228
- 453 Methylthioadenosine is Not Dramatically Elevated inMTAP-Homozygous Deleted Primary Glioblastomas. 0
- 452 Classification of Brain Tumor IDH Status using MRI and Deep Learning. 1

- 451 A Local-Network Guided Linear Discriminant Analysis for Classifying Lung Cancer Subtypes using Individual Genome-Wide Methylation Profiles. **2020**, 676-687
- 450 Imaging Genomics. **2020**, 223-239
- 449 Idh-1 Status and Venous Thromboembolism in Glioma Patients. **2019**, 1-5
- 448 Chemotherapy and Future Developments. **2020**, 29-37
- 447 Comprehensive analysis of lncRNAs reveals candidate prognostic biomarkers in multiple cancer types.
- 446 Cerebellar glioblastoma multiforme in an adult patient with neurofibromatosis type 1: an extremely rare report with review of literature. **2019**, 55,
- 445 Glutamate in cancers: from metabolism to signaling. **2019**, 34, 260-270 6
- 444 The importance of molecular genetics for cancer screening. **2020**, 49, 86-93
- 443 The Basic Molecular Genetics and the Common Mutations of Brain Tumors. **2020**, 93-104
- 442 Brain Tumour Imaging: Developing Techniques and Future Perspectives. **2020**, 81-92
- 441 Genome Medicine for Brain Tumors: Current Status and Future Perspectives. **2020**, 60, 531-542 2
- 440 An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity.
- 439 Recent perspectives of molecular aberrations in pediatric high-grade glioma. **2020**, 72, 116-122
- 438 Brain Tumor IDH, 1p/19q, and MGMT Molecular Classification Using MRI-based Deep Learning: Effect of Motion and Motion Correction. 2
- 437 The novel, recurrent mutation in the TOP2A gene results in the enhanced topoisomerase activity and transcription deregulation in glioblastoma. 1
- 436 Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling.
- 435 The ketogenic diet is not effective in preclinical models of IDH1 wild-type and IDH1 mutant glioma.
- 434 Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids. **2020**, 27, 4039-4061 2



433	A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors.	
432	Behandlung von Gliomen - die neurochirurgische Perspektive. <b>2020</b> , 23, 29-34	
431	Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. <b>2021</b> , 13,	2
430	Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation. <b>2021</b> ,	0
429	Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. <b>2021</b> , 4, 1243	3
428	Metabolic Changes and Their Characterization. <b>2020</b> , 35-70	
427	Carbonic anhydrase IX as a marker of hypoxia in gliomas: A narrative review. <b>2020</b> , 3, 97	0
426	CKAP2L Knockdown Exerts Antitumor Effects by Increasing miR-4496 in Glioblastoma Cell Lines. <b>2020</b> , 22,	5
425	Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?.	0
424	Radiotherapy in Brain Tumors. <b>2021</b> , 313-334	1
423	RIOK2 drives glioblastoma cell proliferation by modulating MYC through the RNA-binding protein IMP3.	0
422	ONCOLYTIC VIROTHERAPY IN GLIOBLASTOMA TREATMENT: PROGRESS AND CHALLENGES IN CLINICAL RESEARCH (LITERATURE REVIEW). <b>2020</b> , 19, 133-140	
421	Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells. <b>2020</b> , 231-255	
420	The Genomic Landscape of Meningiomas. <b>2020</b> , 35-55	1
419	Survival Benefit of Supratotal Resection in a Long-term Survivor of -wildtype Glioblastoma: A Case Report and Literature Review.. <b>2021</b> , 8, 747-753	0
418	All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. <b>2020</b> , 61, 762-773	3
417	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. <b>2020</b> , 2, vdaa151	0
416	Cerebral Gliomas. <b>2020</b> , 1853-1875	

- 415 Improved risk stratification in younger wild-type glioblastoma patients by combining a 4-miRNA signature with promoter methylation status. **2020**, 2, vdaa137 0
- 414 Diffuse Astrocytic and Oligodendroglial Tumors. **2020**, 15-72
- 413 Central Nervous System. **2020**, 1243-1320
- 412 Glioblastoma. **2020**, 173-182
- 411 Metabolic Pathways of Eukaryotes and Connection to Cell Mechanics. **2020**, 825-891 0
- 410 Pathogenic and Therapeutic Role of Micrnas in Glioblastoma Multiforme. **2020**, 8, 107-118
- 409 Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment. **2021**, 8, 60-76
- 408 SOCS proteins and their roles in the development of glioblastoma. **2022**, 23, 5 1
- 407 Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study. **2021**, 1-9 1
- 406 Cancer Cell Metabolism Featuring Nrf2. **2020**, 17, 263-271
- 405 Functional Exploration of Copy Number Alterations in a Drosophila Model of Triple Negative Breast Cancer.
- 404 LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma. **2020**, 98, 556-564 1
- 403 Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm. **2021**, 45, 137-142 1
- 402 Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population. **2020**, 15, e0242793
- 401 Expression of CD44 and IDH1 R132H in Gliomas and their Prognostic Relevance. **2020**, 74, 318-324
- 400 Impact of the next generation DNA sequencers. **2009**, 2, 193-202 6
- 399 Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. **2011**, 3, 251-8 1
- 398 Systems approaches to molecular cancer diagnostics. **2010**, 10, 531-42 5

397	The evolving picture of the glioblastoma genome. <b>2010</b> , 1, 237-8	4
396	Glioblastoma genetics: in rapid flux. <b>2010</b> , 9, 125-31	10
395	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. <b>2013</b> , 3, 29-51	35
394	Role of SOX family of transcription factors in central nervous system tumors. <b>2014</b> , 4, 312-24	41
393	Molecular biology of gliomas: present and future challenges. <b>2014</b> , 10, 29-37	30
392	A mathematical model for short-term vs. long-term survival in patients with glioma. <b>2014</b> , 4, 862-73	8
391	Genetics of colorectal cancer. <b>2014</b> , 7, 507-11	13
390	Aldehyde dehydrogenase 1A1 circumscribes high invasive glioma cells and predicts poor prognosis. <b>2015</b> , 5, 1471-83	13
389	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. <b>2015</b> , 8, 11485-94	8
388	Identifying the genes regulated by IDH1 via gene-chip in glioma cell U87. <b>2015</b> , 8, 18090-8	2
387	Assessment of epidermal growth factor receptor status in glioblastomas. <b>2013</b> , 1, 47-52	
386	MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras. <b>2017</b> , 7, 982-998	20
385	In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme. <b>2017</b> , 42, 258-265	7
384	Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors. <b>2016</b> , 17, 5195-5201	7
383	Errestin 1 Overexpression Increases Temozolomide Resistance in Human Malignant Glioma Cells. <b>2017</b> , 43, 112-119	1
382	Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing. <b>2019</b> , 5,	2
381	Integrated Cancer Subtyping using Heterogeneous Genome-Scale Molecular Datasets. <b>2020</b> , 25, 551-562	1
380	Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas. <b>2020</b> , 13, 230-238	4

379	[Isocitrate dehydrogenase mutation in acute myeloid leukemia]. <b>2015</b> , 36, 82-4	
378	Identification of three glioblastoma subtypes and a six-gene prognostic risk index based on the expression of growth factors and cytokines. <b>2020</b> , 12, 4669-4682	3
377	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. <b>2020</b> , 20, 351	
376	Lomustine Loaded Superparamagnetic Iron Oxide Nanoparticles Conjugated with Folic Acid for Treatment of Glioblastoma Multiforma (GBM). <b>2020</b> , 19, 134-144	1
375	Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?. <b>2021</b> , 11,	2
374	Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. <b>2022</b> , 32, 42-53	1
373	Oncometabolites as Regulators of DNA Damage Response and Repair. <b>2022</b> , 32, 82-94	0
372	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <b>2021</b> , 155, 363-372	2
371	Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. <b>2021</b> ,	5
370	The effects of altered neurogenic microRNA levels and their involvement in the aggressiveness of periventricular glioblastoma. <b>2021</b> ,	
369	Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery. <b>2021</b> , 19, 378	5
368	CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target. <b>2021</b> , 100, e27931	1
367	Establishment of patient-derived organoid models of lower grade glioma. <b>2021</b> ,	4
366	Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. <b>2021</b> , 155, 343-351	0
365	Molecular pathological recognition of freshly excised human glioma using terahertz ATR spectroscopy.. <b>2022</b> , 13, 222-236	1
364	Single-cell transcriptome identifies molecular subtype of autism spectrum disorder impacted by de novo loss-of-function variants regulating glial cells. <b>2021</b> , 15, 68	2
363	Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. <b>2021</b> ,	0
362	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib. <b>2021</b> ,	2

361	[The 2021 WHO classification of tumours of the central nervous system]. <b>2021</b> ,	1
360	De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma.	0
359	Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models. <b>2021</b> , 11, 10047-10063	1
358	Prostate Apoptosis Response-4: a Therapeutic Target for Malignant Gliomas. <b>2021</b> , 77-111	
357	TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas.. <b>2022</b> ,	1
356	Synthesis and biological evaluation of novel PET tracers [F]AG120 & [F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. <b>2021</b> , 53, 116525	0
355	Age influences on the molecular presentation of tumours.. <b>2022</b> , 13, 208	1
354	Post-translational modifications on mitochondrial metabolic enzymes in cancer.. <b>2021</b> , 179, 11-23	1
353	Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.. <b>2021</b> , 119, 105569	0
352	Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.. <b>2021</b> , 167, 1-6	0
351	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. <b>2020</b> , 20, 1-1	0
350	Immunotherapy for Neuro-oncology.. <b>2021</b> , 1342, 233-258	1
349	Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?. <b>2021</b> , 11, 572	5
348	Circular RNAs and glioblastoma multiforme: focus on molecular mechanisms.. <b>2022</b> , 20, 13	2
347	Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma.. <b>2021</b> , 15, 791776	0
346	Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation.. <b>2022</b> , 4, vdac004	
345	The influence of the blood-brain barrier in the treatment of brain tumours.. <b>2022</b> ,	2
344	Meta-analysis of whole-genome gene expression datasets assessing the effects of IDH1 and IDH2 mutations in isogenic disease models.. <b>2022</b> , 12, 57	0

343	DNA Methylation-Driven Genes for Developing Survival Nomogram for Low-Grade Glioma.. <b>2021</b> , 11, 629521	3
342	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma.. <b>2022</b> , 4, vdac002	0
341	Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?. <b>2022</b> , 14,	0
340	The phosphatase and tensin homolog gene inserted between NP and P gene of recombinant New castle disease virus oncolytic effect test to glioblastoma cell and xenograft mouse model.. <b>2022</b> , 19, 21	0
339	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types.. <b>2022</b> , 14,	0
338	Central Nervous System Tumors. <b>2022</b> , 123-157	
337	Ceramide Composition in Exosomes for Characterization of Glioblastoma Stem-Like Cell Phenotypes.. <b>2021</b> , 11, 788100	0
336	Neurofibromin and suppression of tumorigenesis: beyond the GAP.. <b>2022</b> ,	0
335	LY294002 Inhibits Intermediate Conductance Calcium-Activated Potassium (KCa3.1) Current in Human Glioblastoma Cells.. <b>2021</b> , 12, 790922	0
334	Clinical development of metabolic inhibitors for oncology.. <b>2022</b> , 132,	5
333	VRK1 is a Paralog Synthetic Lethal Target in VRK2-methylated Glioblastoma.	0
332	The Distribution and Significance of IDH Mutations in Gliomas.	
331	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.. <b>2022</b> , 12, 1078	1
330	Serum Inflammatory Biomarkers Contribute to the Prognosis Prediction in High-Grade Glioma.. <b>2021</b> , 11, 754920	
329	Brain tumor IDH, 1p/19q, and MGMT molecular classification using MRI-based deep learning: an initial study on the effect of motion and motion correction.. <b>2022</b> , 9, 016001	1
328	An Enzymatic Biosensor for the Detection of D-2-Hydroxyglutaric Acid in Serum and Urine.. <b>2022</b> , 12,	1
327	Medicina de precisión: rol de la anatomía patológica en diagnóstico y tratamiento personalizado. <b>2022</b> , 33, 36-43	
326	New Approaches with Precision Medicine in Adult Brain Tumors.. <b>2022</b> , 14,	1

325	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.. <b>2021</b> , JCO21020360	
324	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas. <b>2021</b> ,	1
323	Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies.. <b>2022</b> , 8, eabm6247	2
322	Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas. 79,	3
321	Polymorphisms in autophagy genes are genetic susceptibility factors in glioblastoma development.. <b>2022</b> , 22, 146	1
320	Glioma targeted therapy: insight into future of molecular approaches.. <b>2022</b> , 21, 39	26
319	The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.. <b>2022</b> , 17, e0257725	0
318	Doramectin inhibits glioblastoma cell survival via regulation of autophagy and .. <b>2022</b> , 60,	0
317	Gamma distribution model of diffusion MRI for evaluating the isocitrate dehydrogenase mutation status of glioblastomas.. <b>2022</b> , 20210392	
316	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?. <b>2021</b> , 13,	1
315	Ferroptosis related genes are regulated by methylation and predict the prognosis of glioblastoma patients.. <b>2022</b> , 11, 603-614	0
314	Analysis of the expression and prognostic value of MT1-MMP, $\alpha$ -integrin and YAP1 in glioma.. <b>2022</b> , 17, 492-507	2
313	Simultaneous brain tumor segmentation and molecular profiling using deep learning and T2w magnetic resonance images. <b>2022</b> , 57-79	
312	Tratamiento integral de los epileptomas y tumores asociados a epilepsia a largo plazo. <b>2022</b> , 67, 29-33	
311	Tumor Heterogeneity and Molecular Characteristics of Glioblastoma Revealed by Single-Cell RNA-Seq Data Analysis.. <b>2022</b> , 13,	0
310	Glioblastoma Microenvironment and Cellular Interactions.. <b>2022</b> , 14,	1
309	Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations.. <b>2022</b> , 14,	1
308	Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies.. <b>2022</b> , 14, 31	2

307	Radiomics Profiling Identifies the Incremental Value of MRI Features beyond Key Molecular Biomarkers for the Risk Stratification of High-Grade Gliomas.. <b>2022</b> , 2022, 8952357	2
306	Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study.. <b>2021</b> ,	
305	New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.. <b>2022</b> , 23,	1
304	A phase 1 study of IDH305 in patients with IDH1-mutant acute myeloid leukemia or myelodysplastic syndrome.. <b>2022</b> , 1	2
303	Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.. <b>2022</b> , 13, 734-741	
302	Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.. <b>2022</b> , 23,	1
301	Metabolism-Based Treatments for Managing Cancer. <b>2022</b> , 109-124	
300	Relapsing High-Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options.. <b>2022</b> , 12,	0
299	MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization.. <b>2022</b> , 12, 4183	1
298	Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.. <b>2022</b> ,	0
297	KAT5 activity regulates G0-like states in human gliomas.	
296	Radiogenomic Predictors of Recurrence in Glioblastoma-A Systematic Review.. <b>2022</b> , 12,	
295	Molecular landscape of IDH-wildtype, H3-wildtype glioblastomas of adolescents and young adults (AYA).. <b>2022</b> ,	
294	Overexpression of prothymosin-alpha in glioma is associated with tumor aggressiveness and poor prognosis.. <b>2022</b> ,	0
293	Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.. <b>2022</b> ,	1
292	The influence of cystathionine on neurochemical quantification in brain tumor in vivo MR spectroscopy.. <b>2022</b> ,	0
291	Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma.. <b>2022</b> , 18, 101368	
290	Glioblastoma microenvironment: The stromal interactions.. <b>2022</b> , 232, 153813	1



289	Status of IDH mutations in chondrosarcoma of the jaws.. <b>2022,</b>	
288	A paracrine circuit of IL-1 $\beta$ /IL-1R1 between myeloid and tumor cells drives glioblastoma progression.	3
287	Patient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review.. <b>2022,</b> 11,	
286	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.. <b>2022,</b> 1	0
285	Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.	
284	Applications of chemical exchange saturation transfer MRI in identifying genetic markers in gliomas.. <b>2022,</b> e4731	0
283	Laser Interstitial Thermal Therapy in Grade 2/3 Mutant Gliomas: A Preliminary Report and Literature Review.. <b>2022,</b> 29, 2550-2563	1
282	Controlled microwave-assisted reactions: A facile synthesis of polyfunctionally substituted phthalazines as dual EGFR and PI3K inhibitors in CNS SNB-75 cell line.. <b>2022,</b> 122, 105740	
281	TDABNet: Three-directional attention block network for the determination of IDH status in low- and high-grade gliomas from MRI. <b>2022,</b> 75, 103574	
280	Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.. <b>2022,</b> 215603	0
279	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.. <b>2022,</b> 28, 100790	0
278	Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.. <b>2021,</b> 2, 100469	0
277	Outcome-guided sparse K-means for disease subtype discovery via integrating phenotypic data with high-dimensional transcriptomic data. <b>2022,</b> 71, 352-375	
276	Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment.. <b>2021,</b>	1
275	IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis.. <b>2022,</b> 30, 178-183	1
274	: A New Molecular Marker for the Diagnosis and Prognosis of Glioma.. <b>2021,</b> 11, 608748	2
273	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <b>2022,</b> 24, 358-383	1
272	Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?. <b>2021,</b> 17, e1009055	0

271	In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic Imaging.. <b>2021</b> ,	
270	Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.. <b>2021</b> ,	2
269	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.. <b>2021</b> , 10,	4
268	Isocitrate dehydrogenase gene variants in cancer and their clinical significance. <b>2021</b> ,	2
267	IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.. <b>2022</b> , 70, 83-97	1
266	Tumors of the Glia: Recent Advances. <b>2022</b> , 353-386	
265	Galvanotactic Migration of Glioblastoma and Brain Metastases Cells.. <b>2022</b> , 12,	0
264	Targeting oncometabolism to maximize immunotherapy in malignant brain tumors.. <b>2022</b> ,	1
263	NEDD9 sustains hexokinase expression to promote glycolysis.. <b>2022</b> , 11, 15	0
262	Measurement of Full Diffusion Tensor Distribution Using High-Gradient Diffusion MRI and Applications in Diffuse Gliomas. <b>2022</b> , 10,	0
261	A high-throughput screening assay for mutant isocitrate dehydrogenase 1 using acoustic droplet ejection mass spectrometry.. <b>2022</b> ,	0
260	Pan-cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors.. <b>2022</b> , 60,	0
259	Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis.. <b>2022</b> , 12,	1
258	Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.. <b>2022</b> , 34, 100430	
257	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517	
256	Image_1.tiff. <b>2019</b> ,	
255	Table_1.xlsx. <b>2019</b> ,	
254	Table_2.xlsx. <b>2019</b> ,	

253 Image\_1.TIF. 2019,

252 Image\_2.TIF. 2019,

251 Image\_3.TIF. 2019,

250 Image\_4.TIF. 2019,

249 Table\_1.XLSX. 2019,

248 Data\_Sheet\_1.docx. 2020,

247 Table\_1.docx. 2020,

246 Image\_1.JPEG. 2020,

245 Image\_10.JPEG. 2020,

244 Image\_2.JPEG. 2020,

243 Image\_3.JPEG. 2020,

242 Image\_4.JPEG. 2020,

241 Image\_5.JPEG. 2020,

240 Image\_6.JPEG. 2020,

239 Image\_7.JPEG. 2020,

238 Image\_8.JPEG. 2020,

237 Image\_9.JPEG. 2020,

236 Table\_1.DOCX. 2020,

235 Image\_1.TIF. **2020**,

234 Image\_2.TIF. **2020**,

233 Image\_3.TIF. **2020**,

232 Image\_4.TIF. **2020**,

231 Image\_1.tif. **2021**,

230 Image\_2.tif. **2021**,

229 Image\_3.tif. **2021**,

228 Image\_4.tif. **2021**,

227 Image\_5.tif. **2021**,

226 Image\_6.tif. **2021**,

225 Table\_1.xlsx. **2021**,

224 Data\_Sheet\_1.csv. **2019**,

223 Data\_Sheet\_2.csv. **2019**,

222 Data\_Sheet\_3.csv. **2019**,

221 Data\_Sheet\_4.docx. **2019**,

220 Data\_Sheet\_5.docx. **2019**,

219 table1.docx. **2020**,

218 Image\_1.tif. **2020**,

217 Image\_1.PDF. 2018,

216 Data\_Sheet\_1.docx. 2020,

215 Image\_1.TIF. 2020,

214 Image\_2.TIF. 2020,

213 Image\_3.TIF. 2020,

212 Image\_4.TIF. 2020,

211 Image\_5.TIF. 2020,

210 Image\_6.TIF. 2020,

209 Table\_1.XLSX. 2020,

208 Table\_2.XLSX. 2020,

207 Image\_1.TIFF. 2018,

206 Image\_2.TIFF. 2018,

205 Table\_1.DOCX. 2018,

204 Table\_1.XLSX. 2019,

203 SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.. 2022, ○

202 Prostaglandin F2 receptor inhibitor overexpression predicts advanced who grades and adverse prognosis in human glioma tissue.. 2022, 65, 93-102

201 Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.. 2022,

200 EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.. 2022,

- 199 The immune regulation of BCL3 in glioblastoma with mutated IDH1.. **2022**, 14, 3856-3873 1
- 198 Rare and misincorporated DNA N-methyladenine is a hallmark of cytotoxic stresses for selectively stimulating the stemness and proliferation of glioblastoma cells.. **2022**, 8, 39 1
- 197 Effects of microRNAs and long non-coding RNAs on chemotherapy response in glioma.. **2022**, 11, 473 1
- 196 Associations among smoking, IDH mutations, MGMT promoter methylation, and grading in glioma: a cross-sectional study. **2022**, 11, 473 1
- 195 Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. **2022**, 14, 2393 1
- 194 Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.. **2022**, 11, 473 1
- 193 DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.. **2022**, 11, 473 0
- 192 KINOMO: A non-negative matrix factorization framework for recovering intra- and inter-tumoral heterogeneity from single-cell RNA-seq data. **2022**, 11, 473 0
- 191 The translational challenges of precision oncology.. **2022**, 11, 473 3
- 190 Considerations for personalized neoantigen vaccination in Malignant glioma.. **2022**, 186, 114312 1
- 189 What the eyes cannot see—limitations of current molecular neuropathological interpretations: A primer. **2021**, 4, 46 1
- 188 Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?. **2022**, 14, 2416 4
- 187 Chromatin structure predicts survival in glioma patients.. **2022**, 12, 8221 1
- 186 Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.. **2022**, 11, 473 0
- 185 Prediction of glioma-subtypes: comparison of performance on a DL classifier using bounding box areas versus annotated tumors.. **2022**, 4, 4 0
- 184 Intracranial Tumors. **2022**, 177-199 1
- 183 Dialogue among Lymphocytes and Microglia in Glioblastoma Microenvironment. **2022**, 14, 2632 0
- 182 Updates in IDH-Wildtype Glioblastoma. **2022**, 14, 2632 1

- 181 Exosomal circRNA BTG2 derived from RBP-J overexpressed-macrophages inhibits glioma progression via miR-25-3p/PTEN. **2022**, 13, 2
- 180 (S)-[1N-[2-(3-hydroxy-2-oxo-2,3-dihydro-1H-indol-3-yl)-ethyl]-acetamide Inhibits Neuroglioma Cell Growth Through Inducing Apoptosis.
- 179 Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. **2022**, 1
- 178 Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study. **2022**, 12,
- 177 Clonon Ba mutovan Formy isocitril dehidrogeny 1 u akutn myeloidn leukemie - pbb ivosidenibu. **2021**, 14, 295-298
- 176 Central Nerve System. **2022**, 313-337
- 175 Unconventional Protein Secretion in Brain Tumors Biology: Enlightening the Mechanisms for Tumor Survival and Progression. 10, 1
- 174 Analyse de l'impact des résultats du séquençage de nouvelle génération chez les patients atteints de glioblastome. **2022**,
- 173 Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. **2022**, 13, 0
- 172 2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies. **2022**, 10, 1359 0
- 171 Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. 9
- 170 Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas. **2022**, 12, 1444
- 169 Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. 0
- 168 Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. 1
- 167 Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. 12, 1
- 166 Metabolomic profiles of human glioma inform patient survival.
- 165 Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas. 1
- 164 The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. 0

163	Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q ¶IMPROVE CODEL: the NOA-18 trial. <b>2022</b> , 22,	0
162	i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability. <b>2022</b> , 20, 3511-3521	2
161	Survival Outcomes and Prognostic Factors in Glioblastoma. <b>2022</b> , 14, 3161	3
160	A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas. <b>2022</b> , 11, 3802	1
159	The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK. <b>2022</b> , 20, 418	1
158	Identification of TNFAIP6 as a hub gene associated with the progression of glioblastoma by weighted gene co-expression network analysis.	
157	Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. <b>2022</b> , 14, 3203	4
156	Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report. <b>2022</b> , 20,	
155	Hedgehog signaling regulates the development and treatment of glioblastoma (Review). <b>2022</b> , 24,	
154	Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development. 13,	1
153	Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma. <b>2022</b> , 12,	0
152	Noncanonical (Non-R132H) IDH-Mutated Gliomas.	
151	IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.	0
150	Applications of single-cell multi-omics sequencing in deep understanding of brain diseases. <b>2022</b> , 2,	
149	Metabolic analysis as a driver for discovery, diagnosis, and therapy. <b>2022</b> ,	3
148	FOCAD/miR-491-5p, downregulated by EGR1, function as tumor suppressor by inhibiting the proliferation and migration of gastric cancer cells. <b>2022</b> ,	0
147	The metabolic addiction of cancer stem cells. 12,	0
146	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. <b>2022</b> , 10, 1763	0



- 145 A multimodal domain adaptive segmentation framework for IDH genotype prediction.
- 144 Inter-pathologist Agreement on Diagnosis, Classification and Grading of Canine Glioma.
- 143 Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. **2022**, 23, 8171 0
- 142 An Epigenetic Role of Mitochondria in Cancer. **2022**, 11, 2518 5
- 141 Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma. **2022**, 82, 3061-3076. 6
- 140 Identify metabolism-related genes IDO1, ALDH2, NCOA2, SLC7A5, SLC3A2, LDHB, and HPRT1 as potential prognostic markers and correlate with immune infiltrates in head and neck squamous cell carcinoma. 13, 0
- 139 Drosophila as a toolkit to tackle cancer and its metabolism. 12, 0
- 138 Biochemical and neurosurgical analyses of circulating neuroglobin and somatic mutations in IDH1 gene in patients with traumatic brain injury. **2022**, 9, 413-422
- 137 The Brain Protein Atlas: a conglomerate of proteomics datasets of human neural tissue. 2200127 0
- 136 Recent Progress in Analysis of Intermediary Metabolism by ex vivo  $^{13}\text{C}$  NMR. 0
- 135 Emerging immune-based technologies for high-grade gliomas. 1-24
- 134 Image-based deep learning identifies glioblastoma risk groups with genomic and transcriptomic heterogeneity: a multi-center study.
- 133 Recent advances of IDH1 mutant inhibitor in cancer therapy. 13, 0
- 132 Identification of the Prognostic Signatures for Isocitrate Dehydrogenase Mutant Glioma. **2022**,
- 131 Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI. 12,
- 130 The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function.
- 129 SLFN11 negatively regulates non-canonical NF- $\kappa$ B signaling to promote glioblastoma progression.
- 128 Quaking but not parkin is the major tumor suppressor in 6q deleted region in glioblastoma. 10, 1

- 127 Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. **2022**, 40, 111182 ○
- 126 Human and machine: Better at pathology together?. **2022**, 40, 806-808 ○
- 125 De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. **2022**, ○
- 124 Evaluation of two new highly multiplexed PCR assays as an alternative to next-generation sequencing for IDH1 /2 mutation detection. ○
- 123 Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression. **2022**, 11, 2857 ○
- 122 Colour adaptive generative networks for stain normalisation of histopathology images. **2022**, 82, 102580 ○
- 121 Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis. **2023**, 848, 146895 ○
- 120 Metabolic dysregulation in cancer progression. **2022**, 1-39 ○
- 119 Trans-sulcal, Channel-Based Parafascicular Biopsy Techniques. **2022**, 193-204 ○
- 118 Neuroimaging issues in assessing glioma response to brain tumour therapy. **2022**, 809-819 ○
- 117 Oncometabolites, epigenetic marks, and DNA repair. **2022**, 191-202 ○
- 116 Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma. 10, ○
- 115 Bioactive peptides from venoms against glioma progression. 12, ○
- 114 Multimodal biomedical AI. **2022**, 28, 1773-1784 5
- 113 The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. **2022**, 13, ○
- 112 Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma. ○
- 111 Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas. ○
- 110 Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. **2022**, 10, 1448 ○

109	ENAH regulates survival, self-renewal, and migration of patient-derived primary glioblastoma neurospheres.	0
108	CCDC103: A Novel Biomarker with Potential Prognostic in Glioma.	0
107	Do Extent of Resection and Tumor Volume affect the Overall Survival of Anaplastic Astrocytoma? A Retrospective Study from a Single Center. <b>2022</b> , 10, 2060-2064	0
106	Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme.	0
105	VRK1 is a Synthetic Lethal Target in VRK2-deficient Glioblastoma.	0
104	Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. 13,	0
103	Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis. <b>2022</b> , 29, 6893-6907	0
102	Performance enhancement of MRI-based brain tumor classification using suitable segmentation method and deep learning-based ensemble algorithm. <b>2022</b> , 78, 104018	3
101	Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma. <b>2022</b> ,	0
100	Differential role of Pax6 and its interaction with ShhGli1IDH2 axis in regulation of glioma growth and chemoresistance.	0
99	The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. 12,	0
98	100 years of the Warburg effect: a historical perspective. <b>2022</b> , 29, T1-T13	0
97	Proteomics of Extracellular Vesicle in Glioblastoma. <b>2022</b> , 10, 207	0
96	Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer. <b>2022</b> , 201-237	0
95	Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma: A Case Report and Systematic Review. <b>2022</b> , 44, 5117-5125	0
94	Risk of Glioblastoma Multiforme in Patients Taking Ion Channel Blockers. <b>2022</b> ,	0
93	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.	2
92	Glutarate regulates T cell function and metabolism.	0

91	Cancer Genomics and Evolution. 1-30	0
90	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <b>2022</b> , 15,	1
89	A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors. <b>2022</b> , 2022, 1-13	0
88	Cancer Metabolism. 1-14	0
87	Differentiation Therapy. 1-19	0
86	The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. <b>2022</b> , 23, 13034	1
85	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.	0
84	Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs. <b>2022</b> , 239, 154172	1
83	Laser hyperthermia: Past, present, and future. <b>2022</b> , 24, S42-S51	0
82	Evolvability and emergence of tumor heterogeneity as a spacetime function. <b>2023</b> , 161, 156061	0
81	The Role of DNA Methylation and DNA Methyltransferases in Cancer. <b>2022</b> , 317-348	1
80	Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations. <b>2022</b> , 36, 039463202211392	0
79	Structure and Function of TET Enzymes. <b>2022</b> , 239-267	1
78	Role of DNMTs in the Brain. <b>2022</b> , 363-394	1
77	Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. <b>2022</b> ,	0
76	Targeting IDH1/IDH2 mutations in gliomas. <b>2022</b> , 35, 787-793	1
75	Prediagnostic biomarkers for early detection of glioma using case-control studies from cohorts as study approach. <b>2022</b> , 4, ii73-ii80	0
74	Overlapping pathogenic de novo CNVs in neurodevelopmental disorders and congenital anomalies impacting constraint genes regulating early development.	0

73	Epigenetic basis for PARP mutagenesis in glioblastoma: A review. <b>2023</b> , 938, 175424	0
72	Glioblastoma: the current state of the problem. <b>2019</b> , 10, 28-35	2
71	Multi-view spectral clustering with latent representation learning for applications on multi-omics cancer subtyping.	1
70	Photodynamic therapy for malignant brain tumors in children and young adolescents. 12,	0
69	Assessment and prediction of glioblastoma therapy response: challenges and opportunities.	1
68	Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. <b>2022</b> , 10, 3205	1
67	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). <b>2022</b> , 25,	0
66	Roadmap toward subtype-specific vulnerabilities in adult glioma. <b>2022</b> , 1,	0
65	Impact of extent of resection on survival on Glioblastoma, IDH-wildtype, WHO grade 4 (WHO 2021). Systematic review and meta-analysis. <b>2022</b> ,	0
64	Effects of metabolic cancer therapy on tumor microenvironment. 12,	0
63	Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel. <b>2022</b> , 25,	0
62	Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033.	0
61	Three-Dimensional Cell Culture Systems in Pediatric and Adult Brain Tumor Precision Medicine. <b>2022</b> , 14, 5972	0
60	Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. <b>2023</b> , 15, 531	0
59	Signaling pathways in brain tumors and therapeutic interventions. <b>2023</b> , 8,	0
58	Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma.	1
57	Genetic evolution and cellular interactions within the tumour microenvironment determine glioblastoma progression. 12, 52	0
56	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. 12,	0

- 55 Cytotoxic steroidal glycosides from the roots of *Paris verticillata* M.Bieb. **2023**, 53, 231-238 ○
- 54 Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center. ○
- 53 Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study. **2023**, 12, 196 ○
- 52 New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme. 866-888 ○
- 51 Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants. 12, ○
- 50 Genomics and Epigenomics in the Molecular Biology of Melanoma: A Prerequisite for Biomarkers Studies. **2023**, 24, 716 ○
- 49 YAP nuclear translocation is regulated by EGFR activation through PTEN/AKT axis in glioblastomas. **2023**, 100053 ○
- 48 Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas. ○
- 47 Updates on the WHO diagnosis of IDH-mutant glioma. ○
- 46 Clinically relevant concurrent BRAF and MEK inhibition alters differentiation states and sensitizes BRAF V600E-mutated high-grade gliomas to immune checkpoint blockade. ○
- 45 Metabolomic profiles of human glioma inform patient survival. ○
- 44 Identifying genetic variants regulating MGMT gene expression - A study in monozygotic Danish twins. **2023**, 115, 110616 ○
- 43 Comparative analysis between high-grade serous ovarian cancer and healthy ovarian tissues using single-cell RNA sequencing. 13, ○
- 42 Prediction of IDH mutation status of glioma based on terahertz spectral data. **2023**, 295, 122629 ○
- 41 Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?. **2023**, 55, 302-314 ○
- 40 D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase. **2023**, 42, 112067 ○
- 39 Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. **2023**, 18, e0281166 ○
- 38 MUC17 mutations are associated with poor prognosis in both adult low-grade glioma and glioblastoma patients. ○

- 37 The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. **2023**, 13, 1438-1466 ○
- 36 MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas. **2023**, 15, 951 ○
- 35 Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment. **2023**, 12, 547 ○
- 34 Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial. **2023**, 15, 1239 ○
- 33 Glioblastoma and Other Primary Brain Malignancies in Adults. **2023**, 329, 574 ○
- 32 PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas. **2023**, 8, ○
- 31 Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. **2023**, 13, ○
- 30 Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. ○
- 29 Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using HydrogenDeuterium Exchange Mass Spectrometry. **2023**, 62, 1145-1159 ○
- 28 Prediction of IDH1 Gene expression in Glioblastoma Using Machine Learning Techniques. **2022**, ○
- 27 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178 ○
- 26 L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis. **2023**, 42, 1294-1307 ○
- 25 The Role of Long Noncoding RNAs in Glioblastoma: What the Neurosurgeon Should Know. **2023**, Publish Ahead of Print, ○
- 24 Identification of Genetic Alterations in Rapid Progressive Glioblastoma by Use of Whole Exome Sequencing. **2023**, 13, 1017 ○
- 23 Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme. **2023**, 12, 897 ○
- 22 Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: A case report. ○
- 21 Clinicopathologic Features of IDH2R172M Mutated Myeloid Neoplasms. ○
- 20 Regulation of redox profile and genomic stability by physical exercise contributes to neuroprotection in mice with experimental glioblastoma.. ○

- 19 Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. **2023**, 24, 6184 ○
- 18 Vasari Scoring System in Discerning between Different Degrees of Glioma and IDH Status Prediction: A Possible Machine Learning Application?. **2023**, 9, 75 ○
- 17 Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. **2023**, 28, 2890 ○
- 16 A pan-cancer analysis of the role of WDFY2 in human tumors. 1-16 ○
- 15 Brain endothelial cell-derived extracellular vesicles with a mitochondria-targeting photosensitizer effectively treat glioblastoma by hijacking the blood-brain barrier. **2023**, ○
- 14 Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report. 13, ○
- 13 Thirty years of progress in the management of low-grade gliomas. **2023**, ○
- 12 Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma. **2023**, 23, ○
- 11 INHBB promotes tumor aggressiveness and stemness of glioblastoma via activating EGFR signaling. **2023**, 154460 ○
- 10 Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. **2023**, 24, 7076 ○
- 9 BRD4: New hope in the battle against glioblastoma. **2023**, 191, 106767 ○
- 8 Flavopiridol suppresses cell proliferation and migration and induces apoptotic cell death by inhibiting oncogenic FOXM1 signaling in IDH-wild type and -mutant GBM cells. ○
- 7 Personalised therapeutic approaches to glioblastoma: A systematic review. 10, ○
- 6 Metabolic Rewiring in Adult-Type Diffuse Gliomas. **2023**, 24, 7348 ○
- 5 Circ\_0067934 as a novel therapeutic target in cancer: From mechanistic to clinical perspectives. **2023**, 154469 ○
- 4 Low-coverage and cost-effective whole-genome sequencing assay for glioma risk stratification. ○
- 3 Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors. **2023**, 147-200 ○
- 2 The intra-tumoral heterogeneity in glioblastoma is a limitation for prognostic value of epigenetic markers?. ○



- 1 An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?. 13,

o